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ABSTRACT 
Establishing efficient methods for local administration of drugs to the inner ear has 
great clinical relevance for the management of inner ear disorders. However, the 
administration route remains a critical issue. The most feasible approach for 
a non invasive drug delivery to the inner ear is application of medication to the middle 
ear cavity on the promise that it will diffuse through the thin round window membrane 
(RWM) separating the inner ear from the middle ear cavity. Gene therapy represents 
a promising future in otology and offers an exciting therapeutic alternative as it could 
be used in prevention or management of cochlear disorders. Also for a gene therapy 
approach, RWM application seems most feasible administration route. Exploring and 
characterizing the RWM route of administration is thus a fundamentally important area 
of research for the development of future treatment of inner ear disorders. 
The objectives of the thesis were to evaluate the efficacy of two drug and gene 
delivering vehicles to the inner ear, sodium hyaluronate (HYA) and chitosans, which 
can be applied to the cochlea. Ultimate aim is to establish an efficient drug delivery 
system and gene transfection for the inner ear. HYA and chitosans loaded with the 
ototoxic drug neomycin as tracer for drug release have been instilled into the middle ear 
of the guinea pigs. Effects on RWM and cochlear hair cells were evaluated after 
a single instillation of HYA (day 7 and 28), chitosans and saline solution (day 7). The 
hearing organ was analysed for hair cell loss and the thickness and ultrastructural 
properties of the RWM were analysed by light and transmission electron microscopy. 
The in vitro transfection efficiency of chitosan was tested by exposing organotypic 
cultures of the organ of Corti, prepared from postnatal day 2 rats, to chitosan carrying 
plasmid DNA (pDNA). The in vivo transfection efficiency was tested at one day or 
seven days after infusing chitosan/pDNA polyplexes with the use of osmotic pumps 
into the cochlea of adult guinea pigs. Tissue analysis was made by 
immunohistochemsitry and RT-PCR. 
HYA and chitosans, especially glycosylated derivative, are safe vehicles that can be 
used for drug transport into the inner ear through the RWM. Both vehicles successfully 
released the loaded neomycin, which exerted toxic effects on cochlear hair cells in 
a degree depending on the concentrations used. The vehicles per se had no noxious 
effect on the cochlear hair cells but they provoked a comparable effect on the thickness 
and morphology of the RWM. The thickness of the RWM returned to normal 4 weeks 
after exposure to HYA. Chitosan as a carrier for inner ear transfection, was associated 
with inconsistent transfection in vitro and in vivo. 
The importance of the RWM as a portal for local therapy of inner ear disorders is 
highlighted in this thesis by focusing on efficiency and effects of the vehicles, applied 
to the RWM for delivering biologically active agents into the cochlea.  
The difficulties and variability associated with applying substances to the RWM were 
explored. The results of this thesis add new knowledge concerning mechanisms of 
passage of biologically active agents through the RWM and may help us to better 
understand the role of RWM in the local cochlear therapy and problems of local 
treatment of inner ear diseases. 
 
Key words: Round window membrane, sodium hyaluronate, chitosan, local cochlear 
drug delivery and gene delivery. 
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1 INTRODUCTION 
The inner ear, the innermost part of the ear, is embedded deeply in the skull within the 
temporal bone. This anatomic position protects the inner ear from external injury. 
However, this isolation has greatly limited the possibility to treat inner ear disorders 
pharmacologically. Treatment of inner ear disorders through systemic administration is 
ineffective due to certain physiological and anatomical barriers such as limited cochlear 
blood supply and the presence of the blood-cochlear barrier. These barriers limit access 
of the therapeutic agents into the inner ear, compromising the availability of the drugs 
in adequate concentration for the target cells within the hearing organ, the organ of 
Corti. In addition, systemic drug administration is associated with increased risk of 
systemic side effects.  
However, the treatment of inner ear disorders represents a promising future in otology. 
The research into strategies to restore hearing following hair cell death and mechanisms 
underlying hearing impairment, have provided new alternative biological therapeutic 
means (local cochlear pharmacological therapy and gene therapy) and led to significant 
progress in the development of local methods of drug and gene delivery to the inner 
ear. Accessing the cochlea via the round window membrane (RWM) is probably the 
most direct and non-invasive approach and has great clinical relevance and potential 
even in a relatively short perspective. Experimentally, several therapeutic agents have 
been tested and shown efficacy in prevention of ototoxicity and noise induced 
sensorineural hearing loss [1-4]. Clinically, there is an increasing interest in local 
application of drugs e.g. gentamicin and steroids directly to the inner ear across the 
RWM for the treatment of inner ear disorders such as Ménière's disease, sudden 
sensorineural hearing loss (SSNHL), and tinnitus [5-12]. For a possible clinical use, 
RWM administration seems most feasible but we lack an efficient and safe way of 
administration of drugs into the inner ear. The importance of the RWM for local 
therapy of inner ear disorders is highlighted in this thesis by focusing on the effects of 
biocompatible polymers (sodium hyaluronate [HYA] and chitosan) applied to the 
RWM for delivering biologically active agents into the inner ear. 
 
1.1 EAR AND HEARING 
The ear is a unique sensory organ that comprises both the hearing organ and the 
vestibular system, which is responsible for maintaining the body balance. 
Anatomically, the ear is composed of the external, the middle ear and the inner ear 
while functionally it is divided into two parts, conduction (external and middle ear) and 
perception (inner ear) parts (Fig.1). All parts have an essential role in the hearing 
process.  
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1.1.1 The external ear  
The external ear composed of the pinna (auricle) and the S-shaped external auditory 
canal which is about 26 mm long in an adult human.  
 
1.1.2 The middle ear  
The middle ear or tympanic cavity is an air-filled cavity behind the tympanic 
membrane. It comprises the tympanic membrane and the three auditory ossicles; the 
malleus, the incus, and the stapes which transmit acoustic vibrations from tympanic 
membrane to the inner ear. It is separated by the tympanic membrane from the external 
ear. Anteriorly it is connected with the nasopharynx through Eustachian tube. The 
medial wall is formed by the promontory which is the basal turn of the cochlea.  
 
1.1.3 The inner ear  
The inner ear, a complex structure with delicate anatomy, is embedded and protected 
deep within the skull in the petrous portion of temporal bone, which is the densest bone 
in the human body. The inner ear is formed by fluid-filled bony and membranous tubes 
which are divided into two functionally separate parts, the cochlea (sensory hearing 
organ) and the equilibrium organs. The bony labyrinth has three sections: the cochlea; 
the semicircular canals and the vestibule. Within the bony labyrinth there is a second 
series of delicate membranous tubes, called the membranous labyrinth, having the same 
parts as the bony labyrinth. The sensory organs contain mechano-receptive cells called 
hair cells.  
 
1.1.3.1 The cochlea 
The mammalian cochlea is snail-shaped organ with a series of fluid-filled 
compartments and two windows (oval and round). The cochlea transforms mechanical 
energy into electrical energy by converting fluid movement into neural impulses. 
The cochlea is broad at the base and gets narrow towards the apex. In human it is 
31-33-mm long with two and a half turns. The length and number of turns differ 
between species. The interior of the cochlea (Fig.2) is divided by basilar and Reissner’s 
membranes into three fluid-filled compartments; scala tympani (ST), scala vestibuli 
(SV) and scala media (SM). These compartments wind helically around the central 
body axis of the cochlea, the modiolus and are filled with two different types of fluids. 
The SM is filled with endolymph, a filtrate of the perilymph, which has an ionic 
composition similar to the intracellular fluid with high potassium concentrations and 
Figure 1. Anatomy of the human ear.  
Adapted from http://commons.wikimedia.org/ 
wiki/File: Anatomy_of_the_Human_Ear.svg 
Released under the Creative Commons 
Attribution 2.5 Generic license.  
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low sodium concentrations. The unique intracellular ionic composition of the 
endolymph is kept constant by the epithelium of stria vascularis [13-18]. 
Stria vascularis is responsible for maintaining the high potassium concentration and 
positive endocochlear potential in SM (80-100 mV). Also the cells lining SM are 
connected with each other by tight junctions, which help the SM to retain the 
endocochlear potential [19,20].  
ST and SV are filled with perilymph which is similar to cerebrospinal fluid in 
consistency. The volume of perilymph in the human is about 70 µl, with around 40 µl 
in the ST [16]. ST and SV are connected together at the helicotrema, a small opening at 
the apex of the cochlea.  
The basilar membrane stretches between the osseous spiral lamina and lateral cochlear 
wall. The hearing organ (organ of Corti) is located on it. The basilar membrane is 
broad, thin and rigid at the base of cochlea while it is narrow, thick and floppy at the 
apex of the cochlea. Stria vascularis is a highly vascularized and metabolically active 
tissue forming the lateral wall of SM. The round window is closed by the round 
window membrane (RWM) which is very compliant, capable of bulging into the 
middle ear. It separates perilymph in the ST from the middle ear cavity. The oval 
window closed by the foot-plate of stapes, is located at the beginning of the SV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.3.2 Organ of Corti 
The hearing organ is very delicate and complicated. It rests on the basilar membrane 
and is covered by a gelatinous like membrane, the tectorial membrane which overlies 
the organ of Corti (Fig.2). Organ of Corti is formed by few thousands of hair cells and 
supporting cells. The hair cells lie within a matrix of supporting cells and are separated 
from each other by the supporting cells. The supporting cells ensure efficient 
mechanical contact between the hair cells and basilar membrane.  
Hair cells, specialized mechanoreceptors, are very precisely organized into one row of 
the inner hair cells (IHCs) and three rows of outer hair cells (OHCs). In human there 
are about 15000-16000 hair cells (3500 IHC and 12000 OHC) in each cochlea while 
the guinea pig cochlea contains 8500-9500 hair cells (1900 IHCs and 6600 OHCs) 
[21,22]. The cochlear hair cells have fine stereocilia (80 cilia per cell) on their apical 
surfaces which project towards and partly embedded in the tectorial membrane [23]. 
The hair cells are frequency-specific and tonotopically organized; those that respond to 
Figure 2. Schematic illustration of a cross 
section view through one turn of the cochlea, 
showing the endolymphatic and 
perilymphatic spaces, as well as the organ of 
Corti and its inner and outer hair cells. 
Adapted from:http://commons.wikimedia.org/wiki
/File: Cochlea-crosssection.png. Released under 
the GNU Free Documentation License. 
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high frequency sound are located at the base of the cochlea and those that respond to 
low frequency sound are at the apex. 
The OHCs are tall cylindrical cells with basally located nuclei and peripherally 
distributed cytoplasmic mitochondria. The IHCs are rounded cells with central nuclei 
and evenly distributed mitochondria in the cytoplasm. 
 
1.1.3.3 The spiral ganglion neurons (SGN) 
The cell bodies of the auditory neurons, spiral ganglion neurons (SGN), are situated in 
the Rosenthal’s canal which is a spiral canal in the modiolus.  
The bipolar SGN send peripheral processes to the hair cells in the cochlea and axons to 
the second-order neurons, the cochlear nuclei, in the brainstem. The auditory nerve 
(cochlear nerve) composed of bundles of bipolar auditory neurons, form part of the 
eighth cranial nerve (CN VIII). The hair cells form synapses with efferent and afferent 
nerve fibers. IHCs are connected to the afferent nerve fibers and the OHCs to the 
efferent nerve fibers [24,25]. There are two types of SGNs. Type I (90-95%) 
myelinated neuron that participate in the afferent innervation of the IHCs and therefore 
conveying most of the afferent input in the brain stem. Ten to 20 type I neurons 
converge on each IHC. Type II (5-10%) unmyelinated neuron innervate the OHCs. 
Each axon from the type II neuron contacts about 30 to 60 OHCs within the same row 
[22,26]. 
 
1.1.3.4 Blood-cochlear barrier  
Most of the cochlea is separated from the systemic circulation by the blood-cochlear 
barrier which is similar to the blood-brain barrier [27,28]. This barrier consists of the 
lining endothelial cells of the capillary blood vessels connected with tight junctions 
thus substances in systemic circulation face physical barriers to gain access to inner ear. 
The cell lining of the stria vascularis are connected with tight junctions and constitutes 
part of the blood-cochlear barrier [29-31]. Thus, a pharmacological substance 
administered to the systemic circulation, must pass through the capillary endothelium 
before it enters the inner ear. SM is also surrounded by cells connected by tight 
junctions. Chemicals entering SM from the vasculature are supposed to either enter via 
the stria vascularis, or the perilymph. Drugs with high protein binding are less likely to 
gain access to the inner ear compartments. Drugs that are positively charged tend not to 
enter the SM. Drugs with high lipidsolubility cross more readily. 
 
1.2 HEARING  
Hearing, an important special sense in human beings, is essential for normal 
development and essential to conduct many activities. The process of hearing begins 
with the capture of the sound by the auricle that works as a funnel, collecting the sound 
waves that reach the outer ear as air conducted pressure alterations. Sound passes 
through the external auditory canal and elicits a vibratory motion at the tympanic 
membrane. This motion is transmitted through the ossicular chain to the footplate of the 
stapes. The stapes footplate serves as a piston that pushes and pulls upon the fluid in the 
inner ear causing a cyclic increase and decrease in the pressure of the scala vestibuli, 
eliciting a traveling wave along the basilar membrane, from the base to the apex. The 
movements of the basilar membrane create a shear force relative to the parallel sheet of 
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the tectorial membrane resulting in movement and deflection of the stereocilia. As the 
stereocilia move, ion channels open and shut in synchrony with the stereocilia motion. 
The endocochlear potential and the high potassium concentration of SM provide 
a unique environment for the hair cells to transform the mechanical motion into 
electrical potentials. As a result, the hair cells (IHCs) depolarize and release 
neurotransmitter to excite afferent auditory neurons to convert the mechanical sound 
energy into electrical impulses that are propagated along the auditory nerve to the brain. 
The IHCs have central function in hearing and regarded as the primary sensory 
receptors. The OHCs are responsible for sensitivity and frequency tuning properties of 
the hearing organ through their active motor function (cell length changes). 
 
1.3 HEARING LOSS 
Hearing loss, the most common sensory impairment in humans, is a major worldwide 
health problem, affecting people from infancy to old ages. According to the report of 
World Health Organization in 2006, approximately 280 million people are suffering 
from hearing impairment [32]. During the pre-lingual period, approximately 1/1000 
individuals are affected by severe to profound hearing loss. Pre-lingual hearing loss has 
a marked effect on speech acquisition, emotional, social and educational development 
of the children. Later onset of severe hearing impairment seriously compromises the 
quality of life, as the affected individuals may become increasingly isolated socially. 
Hearing loss affects one third of adults over the age of 60 and half of the adults above 
the age of 75 [33,34]. Among the adult population 0.3% manifests a hearing loss 
greater than 65 dB between the ages of 30-50 and this prevalence is continuously 
increasing. In developed countries, at least 10% of the population suffers from hearing 
impairment sufficient to interfere with normal life [35]. Hearing loss is divided into two 
types, conductive and sensorineural hearing loss (SNHL), depending on where or what 
part of the auditory system is damaged.  
In conductive hearing loss the sound is not conducted efficiently by the external ear and 
middle ear to the inner ear. This causes a reduced ability to hear faint sounds. 
Conductive hearing loss often is caused by otitis externa, otitis media, impacted earwax 
(cerumen), or congenital malformations of the external and middle ear. Conductive 
hearing loss can usually be corrected either medically or surgically. 
SNHL accounts for 90% of all hearing loss cases. This type of hearing loss results from 
damage at any point between the cochlear hair cells (cochlear) and the auditory cortex 
in the brain (retrocochlear). The most common affected site is the hair cell. SNHL not 
only involves a permanently reduced ability to hear faint sounds, but may also involve 
low speech discrimination. The causes of SNHL include e.g. inflammatory disease, 
genetic abnormalities, excessive noise, ototoxicity, head injury, infectious diseases, ear 
infection, tumors and aging (presbycusis). Conductive hearing loss occurs in 
combination with SNHL, when there are defects in the conductive and the perceptive 
parts of the ear. The hearing loss is then referred to as mixed hearing loss. 
In the human, the hair cells and neurons do not regenerate spontaneously thus 
restoration of hearing is impossible. Currently, no complete cure exists for SNHL but 
the treatment have focused on functional improvement such as amplification devices 
(hearing aids) and devices that stimulate auditory neurons electrically 
(cochlear implants). These options do not completely restore our ability to hear, but for 
now, are the best options available. 
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1.4 ROUND WINDOW MEMBRANE (RWM) 
The round window membrane (RWM) closes the round window at the basal end of the 
cochlea. Despite being called round membrane, it is triangular in shape. RWM is 
located posteroinferiorly in the medial wall of the middle ear (promontory) within the 
round window (RW) niche which is created by the promontory bony overhang. In 
human, the RW niche has a triangular shape with three walls, anterior (1.5 mm), 
posterior (1.6 mm) and superior (1.3 mm). The average depth of the RW niche is 
approximately 1.5 mm [36]. To simplify, one can think of the RW niche as a well, with 
the true RWM being relatively protected from the middle ear at the bottom [37]. In 
human at the entrance of the RW niche, mucosal folds (false RWM) and fibro-fatty 
tissues could be present in up to one third of individuals. These could partially or 
completely cover the RW niche [38]. The false RWM is a three-layers structure but the 
epithelium on both sides is of the same type [39]. The false RWM and fibro-fatty 
tissues have not been described in other species. The RW niche in these animals is 
shallower and almost the entire RWM can be seen [40-42].  
 
1.4.1 Electron microscopic features of RWM 
The RWM is thicker at the periphery, thinner towards the central part and has a slight 
convexity (protrusion) towards the scala tympani [43-45]. The ultrastructure of the 
RWM consists of three layers: an outer epithelium facing the middle ear, middle layer 
of connective tissue, and an inner epithelium facing the inner ear [39,43,45-48]. The 
outer epithelium is of endodermal origin while the middle connective tissue layer and 
inner epithelium are derived from the mesoderm [41]. 
The outer epithelium consists of a single layer of epithelial cells, which is continuous 
with the middle ear mucosa, and basement membrane. The epithelial cells are low 
cuboidal to flat cells with rounded and centrally located nuclei. The cytoplasm is rich in 
cellular organelles; mitochondria, Golgi complexes, and rough endoplasmic reticulum 
[36,44]. Thin and short microvilli are present on the free surface of the epithelial cells, 
and micropinocytotic vesicles are found both at the apical and the basal sides of the 
cells. The epithelial cells are connected by interdigitations on their lateral walls and 
close to the outer cell surface, there are tight junctions but there are no gap junctions 
between the outer epithelial cells [36,41,43].  
The connective tissue layer consists of fibroblasts, collagen fibers, and elastic fibers 
and it contains blood vessels, lymph vessels and nerve endings [41]. The connective 
tissue layer is thought to be in conjunction with the mucoperiosteum of otic capsule. 
There is gradual increase in number of fibroblasts, collagen fibers and elastic fibers 
towards the inner ear epithelium. Collagen fibers are arranged longitudinally and 
radially in bundles but there are some fibers irregularly arranged. Blood and lymph 
vessels traverse from the edges to the center. The blood vessels of the RWM originate 
from the vascular plexuses of the tympanic mucosa [36,43,45]  
The inner epithelial layer is a continuation of the lining of the scala tympani. The 
epithelial cells are large, flat squamous cells with long lateral extensions which 
overlaps each other giving the appearance of stratification [45]. The intercellular spaces 
are wide, and the cell junctions are loose [49]. Sometime the cells appear to be 
disconnected because of the large spaces. The cells have few organelles and microvilli 
are absent on the cell surface. The cytoplasm contains small pinocytotic vesicles. 
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There is no basement membrane between the inner epithelial cells and the connective 
tissue layer and occasionally pores are seen between inner epithelial cells. 
There are no significant differences in thickness of RWM with aging, but there are 
distinct changes in the ultrastructural characteristics. During infancy, the outer 
epithelium and the inner epithelium are thick and the connective tissue core is 
uniformly cellular, with fibroblasts containing large nuclei, irregularly arranged 
collagen fibers, few elastic fibers; and the ground substance is abundant. With 
increasing age, the RWM get the described characteristic features. In the elderly, there 
is an increase in ground substance; elastic fibers become thicker; and thin elastic fibers 
are absent. [43-45,50]. 
 
1.4.2 RWM measurements 
In human, the average thickness irrespective of age is about 70 µm ranging from 
63-67µm [45,51] or 40-70 µm [36,43]. The average diameter is (2.32 ± 0.19 mm) with 
the long diameter being 2.3 mm (1.8-3.2 mm), short diameter 1.9 mm (1.4-2.4 mm). 
The average surface area has been estimated to be 3.4 mm2 [36,41].  
The RWM of the research animals principally resembles that of the human, but 
substantial differences in thickness of RWM exist between humans (70 µm) and other 
species, being thinnest in rodents. The average thickness of the RWM in small rodents 
has earlier been reported to be between 10-15 µm in the central part and 70 µm in the 
periphery [41,51-57], with thickness of 12 µm for rats [58], 10-14 µm for the chinchilla 
and guinea pigs [54]. In cats, mean thickness of RWM reported to be 20-40 µm; and in 
the rhesus monkey, 40-60 µm [44].  
 
1.4.3 Function of RWM 
The exact function of the RWM is an area of debate and controversy. It may have 
several additional functions but its basic function is to act as a release mechanism to 
permit displacements and fluid pressure changes of the inner ear in conjunction with 
inward movement of the stapes footplate in the oval window during sound stimulation 
[44,50].  
The RWM is regarded to be the main route for passage of substances from the middle 
ear cavity into the inner ear, thus it may serve as a barrier to potentially ototoxic 
substances during infectious processes within the middle ear. [41,44,45,59,60]. It has 
been also suggested that the RWM act as an alternative way for conducting sound to 
the cochlea [44,45]. Moreover, animal studies have suggested that the RWM behaves 
as an active semi-permeable membrane, taking part in secretion into and/or absorption 
from perilymph [41,46,52]. Experimentally, it is known that the RWM is permeable to 
different therapeutic agents and biologically active compounds [45,61-63]. Presence of 
microvilli and organelles in the outer epithelial cells as well as the loose junctions with 
the long lateral extensions of the inner layer cells suggests that the outer and inner 
epithelial layers have an absorptive function [45]. Histopathologic changes in the 
RWM when exposed to injury [51,55] indicate that RWM possibly take part in the 
middle ear, inner ear [45,64] and RW defense system [44,65]. 
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1.4.4 Permeability and passage of substances across RWM 
As the port of entry from the middle ear to the inner ear, the permeability of the RWM 
under normal and pathological conditions has attracted increasing interest [59]. The 
passages of different substances through the RWM in experimental animals have 
proven that the RWM behaves like a semi-permeable membrane. Extensive studies on 
RWM in guinea pigs [36,45,66,67] chinchillas [49,55,68,69], rhesus monkeys and cats 
[55,64] and mongolian gerbils [70] have revealed that the RWM is permeable to water 
[49] antibiotics; especially aminoglycosides, streptomycin, gentamicin and neomycin 
[49,71], chloramphenicol [72], tetracycline [49], antiseptics, arachidonic acid 
metabolites [73], bacterial endotoxins and exotoxins [41,74-77], albumin [49,78,79], 
tracers such as horseradish peroxidase, latex spheres (1-µm), and cationic ferritin 
[44,64,67], local anesthetics [45], glucocorticoids, antioxidants [64] and gases such as 
oxygen [80]. 
Based on the animals studies, a number of factors have been described that may affect 
the permeability and the passage of substances through the RWM [41,44,45,55,59,81].  
Some of these factors are related to the RWM such as thickness, presence of false 
RWM, fibro-fatty tissue plugs [38,39] and inflammation in the middle ear cavity. Other 
factors are related to the substance or the drug such as size, shape, 
molecular weight (MW), the molecular configuration, concentration, liposolubility, 
electrical charge, and contact with the RWM.  
The permeability of substance is affected by the thickness of the RWM which can lead 
to variability in absorption of drugs into scala tympani [49]. Animal studies have shown 
that the degree of passage of substances is higher in rodents and lower in cats [55].  
The severity and duration of the inflammation in the middle ear cavity affects both the 
permeability of the RWM and its thickness [41,60,68,69,78]. Low MW substances can 
traverse the RWM under normal conditions [49,50,59,64,81]. Macromolecules that do 
not pass under normal conditions, may do so during inflammatory process [59,78,82]. 
At an early phase of otitis media, there is a gradual increase in the permeability of the 
RWM [36,49,67-69,78] but at later stages, the changes in the membrane become more 
protective and result in decreased permeability [45,49,51,67-69].  
Passage of different substances through the RWM is by different pathways depending 
on size, structure and electrical charge of the substances. Substances traverse the RWM 
either directly through the cytoplasm, (exotoxin), or as pinocytosis, (cationic ferritin), 
or through channels in between cells, (latex sphere) [45,54]. Low MW substances 
(<1000 MW) such as sodium ions [83], steroids, gentamicin, streptomycin, neomycin, 
and tetracycline are transported actively through the RWM [49]. While, high MW 
substances (>1000 MW) such as albumin, ferritin, and endotoxins can only be 
transported by pinocytosis [54]. Cationic ferritin passes easily through the RWM [64], 
while the anionic ferritin does not pass in rodents [36,44] and cats [55]. There are 
substances that can increase the permeability of RWM and passage of substances from 
middle ear into scala tympani. These include mediators such as histamine [84], 
prostaglandins and leukotrienes [49], pontocaine [45], endotoxin of Escherichia coli 
and exotoxin of Staphylococcus aureus [45,55,78,82,85,86]. On the other hand 
deposition of inflammatory products on RWM reduces the permeability [44,45]. These 
findings have suggested that the passage of substances through the RWM is not only 
a passive transport, but also an active biological passage. 
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1.5 LOCAL INNER EAR THERAPY  
The use of hearing aids and, in more severe-profound hearing loss, surgical 
implantation of cochlear implants are the only treatment options available nowadays for 
the treatment or rehabilitation of sensorineural hearing loss (SNHL). New insights into 
the mechanisms underlying hearing impairment, offered the potential for new 
therapeutic approaches. Advances in the molecular and genetic processes of the 
auditory system have provided alternative means of biological therapy either 
as prevention, protection or intervention treatments for the inner ear. Local 
pharmacological therapy and gene therapy have been suggested as potentially effective 
and promising approach in the treatment of hearing disorders [87-90]. 
 
1.5.1 Local cochlear pharmacological therapy  
Delivery of drugs to the cochlea is problematic as the cochlea is a small sized, 
relatively inaccessible and well isolated from surrounding tissues. Systemic drug 
administration is of limited therapeutic effectiveness and probably not feasible as the 
limited direct blood supply of the cochlea and the blood-cochlear barrier are likely to 
restrict transport of drugs from the serum to cellular targets in the inner ear. Moreover, 
the systemic application of drugs carries the risk of unwanted systemic side effects, 
at least for potent drugs [91]. Large inter-individual variation in responses to systemic 
administration, due to variation in dosage and body metabolism, further limits the use 
of systemic administration [92]. Thus, there is consequently an increasing interest both 
experimentally and clinically in local treatment of inner ear disorders. Local application 
of drugs into the inner ear has several key advantages such as the diseased ear is treated 
directly and higher concentration of drugs can be obtained in the inner ear [85,93-95].  
For alternative biological therapies of cochlear diseases be clinically relevant, it is 
important to develop safe and reliable inner ear delivery methods for the therapeutic 
agents and to establish sustained and effective therapeutic levels within the cochlear 
fluids. Inner ear delivery methods can be divided into intratympanic and intracochlear 
delivery. 
 
1.5.1.1 Intratympanic drug delivery  
Treatment of some well-defined inner ear disorders is becoming more dependent on 
inner ear delivery. As the inner ear is accessible through the round window membrane 
(RWM), one of the options is to apply the drugs directly to the RWM from which the 
active substances are expected to diffuse into the cochlear fluids and thereby to the sites 
of pathological changes [95-98]. This involves perfusion of the middle ear cavity with 
therapeutic agents through the tympanic membrane [99]. It depends on passage of the 
therapeutic agents through the RWM into scala tympani [100]. The intratympanic drug 
delivery started in 1950s for the treatment of Ménière’s disease with streptomycin [31] 
and is still in use for delivery of different agents such as, steroids, aminoglycosides, 
anti-oxidants, and neurotrophins [101,102]. Experimentally, local application of drugs 
to the RWM has been used for a wide variety of therapeutic agents, including steroids, 
anti-oxidants, and neurotrophins. It has been shown that the local application resulted in 
significantly higher levels of substances in the inner ear fluids compared to systemic 
applications [91].  
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The administration of therapeutic agents to the middle ear cavity holds great promise in 
applications ranging from the treatment of Ménière’s disease [103,104] to particular 
preventive strategies (otoprotection with antioxidants) in relation to noise exposure, 
intracochlear surgical trauma, head and neck radiation or treatment with an ototoxic 
drug such as cisplatin and aminoglycoside antibiotics. These are possible areas where 
local administration of antioxidants can be used to prevent the hearing loss. It also 
holds promise in interventive prospective in relation to treatment of sudden 
sensorineural hearing loss SSNHL and autoimmune hearing loss with local 
administration of steroids because the high systemic doses of steroids needed to reduce 
inflammation, cause significant side effects. Future application of local regenerative 
compounds may play a role for regeneration of SGN and hair cells after sensorineural 
hearing loss. 
However, delivery of therapeutic agents in an effective manner to the inner ear is 
difficult and establishing an efficient and controlled administration route remains 
a critical issue, as there is large variability in the reported results of the pre-clinical and 
clinical trials [105]. This variability might result from factors such as middle ear 
volume, leakage, absorption and clearance of the agent from the middle ear cavity via 
the Eustachian tube and by the ciliated mucosa of the middle ear, condition of the 
RWM as well as the availability and contact of the drug with the RWM [12,106]. If the 
drug is placed in the middle ear, the drug can diffuse through the RWM into the inner 
ear but it is important that the drug remains in contact with the RWM for a sufficient 
period of time. Development of a method which deliver a fixed dose and ensures 
contact with the RWM would be of crucial importance for solving the problems 
relating to delivering drugs to the inner ears. Efforts to control the variability and 
overcome the limitations associated with local drug delivery to the inner ear, have had 
led to the development of passive biodegradable sustained-release vehicles and several 
active implantable drug delivery devices to locally deliver the therapeutic agents and 
achieve relatively sustained therapeutic levels in the inner ear.  
Biodegradable polymers, hydrogel and nanoparticle delivery systems have emerged 
as promising topics for delivering substances to the cochlea in a sustained and 
controllable manner. Drugs may be loaded, dispersed within a matrix or contained 
within a reservoir encapsulated by a shell of biodegradable carrier vehicles or polymer. 
The release of the drug is due to either the slow degradation of the material, or drug 
diffusion or a combination of these. As the polymers are biodegradable, they are either 
removed by phagocytic cells of the immune system or drained away. The polymers can 
be tailored through modifications of polymer structure to control the rate of release of 
drugs from polymers. The vehicle can either be applied directly to the RWM or filling 
the whole middle ear cavity. The use of vehicles offer important benefits such as 
extended release of the drugs and extended contacts with the RWM so that the presence 
of the drug within the middle ear can be prolonged in comparison to simple middle ear 
perfusions. In this way the sustained diffusion into the cochlea across the RWM will be 
increased. 
Biodegradable polymer system may consist of degradable microparticles or 
nanoparticles, hydrogels [107], poly lactic co-glycolic acid (PLGA) polymers [108], 
siloxane [95] biodegradable gelatin polymer, gelfoam, [109], alginate [63] and chitosan 
[105,110]. 
Sodium hyaluronate (HYA) enables targeting of tissues through the use of chemical 
(pH or ionic factors), physical (temperature or electrical potential) triggering 
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mechanisms which cause the hydrogel to swell and release the loaded substance in 
a controlled fashion [42,98,107,111-115]. The nanoparticles may be comprised of 
biodegradable PLGA or non-degradable materials [108,116]. Generally, it seems that 
the intratympanic delivery methods are most probably depend on the presence of 
biodegradable vehicles within the middle ear cavity for passive sustained release of 
drugs into the inner ear [106,117].  
Implantable drug delivery systems to locally deliver the drug to the inner include the 
RW Microcatheter and the Silverstein MicroWick. The µ-Cath™ and e-Cath™ 
microcatheters are double or triple-lumen catheters inserted through the tympanic 
membrane and positioned near the RWM under general anesthesia, with ability to 
control both the concentration and flow [7,11,95,118-121].  
Silverstein MicroWick™ is a polyvinyl acetate wick (1 mm thick and 9 mm long) that 
absorbs drugs instilled in the external auditory canal and transports it to the RWM. The 
wick is inserted through a grommet which passes through the tympanic membrane 
under local anesthesia [95,118,122,123].  
 
1.5.1.2 Intracochlear drug delivery  
This approach involves a direct delivery into the cochlea, providing a more direct 
access to sensory cells and neurons. Fluid flow may augment diffusion which could 
provide access to more apical regions of the cochlea, allowing the drugs to reach their 
intended targets more directly than with systemic delivery [124]. Intracochlear drug 
delivery is done by cochleostomy either through the RWM, or direct injection through 
the otic capsule [31,125,126]. While dosage may be precisely controlled, a greater 
possibility of surgical trauma exists. Therefore, delicate approaches are required to 
avoid possible damage from the intracochlear drug delivery approach. 
Advances in direct intracochlear infusions include the use of osmotic pump which 
offers a controlled delivery. Mini-osmotic pumps connected to a micro-cannula makes 
a continuous delivery to the cochlea possible. An osmotic pressure difference between 
a compartment within the pumps (salt sleeve) and the tissue environment in which the 
pump is implanted; cause the pump to work. The delivery rate is controlled by the 
water permeability of the outer membrane of the pump. The compressed reservoir of 
the pump cannot be refilled, which makes it single use only. The molecular weight of 
a compound has no impact on the release rate or function of the pump [127]. 
Alzet osmotic pumps of different reservoir volumes and flow rates are still in 
pre-clinical use [128]. 
 
1.5.2 Cochlear gene therapy 
Gene therapy defined as targeted introduction and regulated expression of a gene that 
will produce certain effect in the host tissue or cell using a genetically engineered 
vector to achieve a biological effect. Gene therapy for the human auditory system is 
a potentially interesting technique for treating both genetic and acquired forms of 
hearing loss, but its use is still limited due to technical and ethical issues 
[129,130].The inner ear constitutes a suitable and unique environment for gene therapy 
because the cochlea is a relatively isolated compartment, which minimizes unwanted 
effects of transfer vectors on other tissues. The limited direct blood supply of the 
cochlea should also reduce the risk of immune responses, and as the cochlea is 
fluid-filled, all of the functionally important cells are easily reached which facilitates 
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a wide transfection of the system. Furthermore, different physiological tools are 
available to assess the auditory function. More than 75 different genes have been 
identified that affect inner ear development or function, could be applicable for gene 
therapy for preservation and regeneration of hair cells [90,131]. Among these genes is 
the mammalian atonal homolog 1 (Atoh1, previously known as Math1), which is 
necessary for hair cell differentiation [132-134]. By re-expressing this gene, supporting 
cells may change cellular phenotype into a hair cell phenotype. The GJB2 is a widely 
expressed gene in the inner ear encoding for a gap junction protein, connexin 26 (cx26). 
This is essential for potassium homeostasis in the cochlea. A mutation in the 
GJB2 gene is a common cause of hearing loss by preventing potassium ions from being 
recycled by the hair cells back to the endolymph leading to potassium intoxication and 
apoptosis of hair cells [19,20]. Cochlear gene therapy could become useful for 
protection of the hearing against ototoxicity, noise exposure, and aging as it can be used 
for delivery of drugs and growth factors to the inner ear, to provide overexpression of 
antioxidants genes [133-137]. 
 
1.5.2.1 Transfer vectors for cochlear gene therapy   
Generally there are two types of gene transfer vectors; viral and non-viral vectors. In 
vast majority of the experiments on gene delivery into the inner ear, viral vectors are 
used. The viral vectors are replication-defective viruses which have specific 
characteristics that make them useful in specific experimental and therapeutic 
application. For example adenovirus has the ability to infect dividing and non-dividing 
cells [138-140], adeno-associated virus with ability to infect non-dividing cells [139-
142], retrovirus with ability to infect dividing cells only, herpes simplex virus [138,143-
146], vaccinia virus [144] and lentivirus which integrates into chromosome of both 
dividing and non-dividing cells [135]. Viral vectors have superior gene delivery 
efficacy but safety concern have arisen. Thus the clinical application of gene therapy is 
somewhat limited by the potentially adverse effects of the virus itself, such as 
immunogenicity, toxicity and possible mutagenesis of the transfected cells [89,136]. 
Thus, using non-viral vector technology would be a safer alternative. Non-viral 
technology includes not only physical vehicles such as liposomes but also approaches 
using gene gun technology and electroporation. The advantages of non-viral vector are 
their ability to form a stable complex with DNA, large gene capacity, and the easiness 
to prepare large amounts. Liposomes can be mixed with DNA for transfection of 
numerous cell types, and introduced into the cochlea via injection [61,147]. Liposomes 
have very low risk of causing an immune response and insertional mutagenesis. But the 
disadvantages are inefficient gene transfer and low rate of transfection [88,135,136]. 
Nanoparticles have been investigated as an alternative to viral vector systems, but carry 
concerns about safety as well as precision of targeting of specific cells and tissues 
[148]. Chitosans form polyelectrolyte complexes with DNA and have been successfully 
used as a non-viral gene delivery system both in vitro and in vivo [149-152]. 
 
1.5.2.2 Delivery routes for cochlear gene therapy 
An efficient delivery system is the corner stone for successful clinical application of 
gene therapy for treatment of hearing disorders. For a possible clinical use, it is not 
enough to identify vectors capable of transfecting inner ear cells but it is essential to 
identify a reliable access route to the inner ear. Since most of the vectors are not able to 
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diffuse through the RWM [31,61,147], most efforts in experimental delivery of gene 
have focused on techniques of delivery to the basal turn of the cochlea through 
a cochleostomy, or by direct injection through the RWM. Higher expression in cochlear 
tissues was achieved via the intracochlear approach when compared to the RWM 
diffusion approach [153]. The intracochlear delivery methods have the advantages of 
a controlled steady cochlear perfusion, but have the disadvantage of potentially 
damaging the architecture of the cochlea. Infusion directly into the scala media resulted 
in efficient expression of the transgene in hair cells, but also death of hair cells around 
the site of inoculation [154]. 
Therefore before moving towards clinical applications it is important to establish 
a method able to provide a uniform distribution throughout the cochlea, selectively 
deliver therapeutic genes to a sufficient number of target cells, not cause any damage, 
preserves cochlear integrity and ensures continued expression of the therapeutic gene 
over an extended period of time [89,90]. These features are crucial in a successful 
application of gene therapy of the inner ear. 
 
1.6 BIODEGRADABLE VEHICLES USED IN THE THESIS  
1.6.1 Sodium hyaluronate (HYA)  
Sodium hyaluronate (HYA) is one of the major components of the extracellular matrix 
in skin, cartilage, synovial fluid and the vitreous humor of the eye. HYA is present in 
the pars flaccida, RWM, annular ligament of oval window, and muscles of middle ear 
[155]. It is a naturally occurring non-sulphated glycosaminoglycan polysaccharide 
consisting of alternating N-acetyl-D-glucosamine and monosaccharides D-glucuronic 
residues [156].  
HYA, molecular weight (5 X 104 – 8 X 106), is a biocompatible and biodegradable 
substance that remains at site of injection over extended period of time [156,157]. 
Experimentally it has been shown that most of the injected HYA into the middle ear 
cavities is eliminated after 28 days [158]. HYA degrades by enzymes called 
hyaluronidases to biocompatible materials. In humans, there are at least seven types of 
hyaluronidase enzymes [157]. HYA is fluid enough to be injected through a fine gauge 
needle into the middle ear. The viscosity of the HYA ensures that HYA remain in 
contact with the mucous membrane for an extended period of time. Then the gel 
produce a rapid burst effect and disintegrate rapidly. The combination of these 
properties together with the known viscoelasticity of HYA facilitates the use of HYA in 
the biomedical field for controlled drug delivery to the inner ear [113]. Intratympanic 
application of dexamethasone with HYA in guinea pigs prolonged the contact with 
RWM and consequently inner ear exposure to dexamethasone [159]. HYA has been 
used also as a drug carrier in several clinical trials for intratympanic dexamethasone 
injection in patients with Ménière’s disease and sudden sensorineural hearing loss, 
SSNHL [160]. The HYA/drug preparation may provide a superior dosage form for 
disorders of the inner ears as HYA controls the release of the dissolved or dispersed 
drug. The loaded substances can be soluble or not soluble in water; they can be of low 
molecular weight or a polymeric substance. These properties of HYA had led us to 
study the effect of HYA on the passage of drugs through the intact RWM (Paper I) and 
on the morphology of the RWM and (Paper IV). 
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1.6.2 Chitosans  
Chitosan, a glycerophosphate hydrogel, (1–4) 2-amino-2-deoxy-b-D glucan, has 
structural characteristics similar to glycosaminoglycans. Chitosans are prepared by 
alkaline N-deacetylation of chitin, which is the main component of the exoskeleton of 
crustaceans. Chitosan can be degraded and metabolized by certain human enzymes, 
especially by lysozyme, and other glycosidases, including certain bacterial enzymes 
produced by intestinal flora [161,162]. The intrinsic properties of a particular chitosan, 
the fraction of acetylated units and the molecular weight have been shown to provide 
a large impact on the physicochemical and biological activities of the polymer 
[163,164]. Intrinsic characteristics of chitosan together with its safety profile as well as 
a range of possibilities for further modification [165,166] make it attractive for 
a variety of biomedical and pharmaceutical applications, including the drug and 
non-viral gene transer delivery [164,167,168]. By being polycationic polymer, 
chitosans can interact and adhere with negatively charged mucosal surfaces and 
macromolecules [164]. This feature facilitates close contact of the therapeutic agent and 
sustained interaction between the mucosal surfaces and the loaded drug in chitosan 
[105,169,170]. It has been also reported that chitosans can open tight junctions 
[149,164,170]. Chitosans have been successfully used as a non-viral gene delivery 
system both in vitro and in vivo [149-152]. The trisaccharide substituted chitosan 
oligomers possess higher gene transfer efficacy compared with unsubstituted oligomers 
[152,171]. Combination of AAM substitution and branching of the backbone of the 
chitosan allow for the preparation of sterically stabilized DNA nanoparticles. The self-
branched glycosylated trisaccharide-substituted chitosan oligomers (SB-TCO) is fully 
soluble at a neutral pH and forms physically stable DNA nanoparticles without 
impairing the intracellular release of DNA [152]. 
These interesting properties of chitosan prompt us to study the efficiency of chitosan to 
deliver biologically active agents into the inner ear as a delivery carrier for the inner ear 
therapy (Papers II and III) and its effect on the morphology of the RWM (Paper IV).  
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2 AIMS  
The objectives of this thesis were to investigate the efficiency of different delivery 
carriers loaded with biologically active agents applied to the cochlea with the ultimate 
aim to establish an efficient and reliable topical drug and gene delivery method to the 
inner ear through using an appropriate carrier vehicle that could be loaded with 
different drugs, and used both for preventive approach against the threat of injury and 
effective treatment of hearing loss and other inner ear disorders. 
 
Paper I:  
1- To evaluate the effect of sodium hyaluronate (HYA) as drug delivering vehicle for 
the inner ear, and to investigate to what extent HYA loaded neomycin as a biomarker 
would diffuse into the inner ear and cause hair cell loss. 
 
2- To determine the safety of intratympanic administration of sodium hyaluronate 
(HYA) to the middle ear by studying the effect of HYA on the cochlear hair cells and 
RWM. 
 
Paper II:  
1- To explore the efficiency of three structurally different types of biodegradable 
chitosan as a delivery carrier for the inner ear.   
 
2- To outline the suitability of intratympanic administration of chitosans into the middle 
ear by studying the effect of chitosans the cochlear hair cells and RWM.  
 
Paper III:  
To evaluate whether expression of a reporter gene can be induced in cochlear cells 
using chitosan as a carrier both in vitro and in vivo. 
 
Paper IV:  
To describe the structure of the guinea pig RWM and to evaluate the changes that may 
occur after application of sodium hyaluronate (HYA), chitosans and saline. 
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3 MATERIALS AND METHODS  
 
3.1 EXPERIMENTAL ANIMALS AND TISSUE PREPARATIONS 
 
3.1.1 Experimental animals 
 
A total of 141 healthy adult albino guinea pigs of both sexes (body weight 250-350 g; 
Lidköpings Kaninfarm, Lidköping, Sweden) and twenty postnatal day 2 Sprague 
Dawley rat pups (Harland, Netherland) were used in papers included in the thesis. 
Albino guinea pigs were used in the in vivo experiments (Papers I-IV) and the 
postnatal day 2 rat pups were used in the in vitro experiments (Paper III). The guinea 
pigs were free from middle ear infections as judged by otomicroscopic inspections. 
They were housed at animal department at the Karolinska University Hospital- Solna. 
They had free access to food and water and housed in temperature-controlled rooms 
with a 12/12 hours light/dark cycle. The animal suffering was minimized in all 
experiments and all animal experiments and procedures were performed in accordance 
with the ethical standards of Karolinska Institutet and consistent with Swedish national 
regulations for the care and use of animals (ethical approvals N334/05, N347/05, 
N32/07, N35/07, N342/07 and N13/10).  
 
3.1.2 Experimental design 
 
The total number of animals, groups, types of treatment used and time of decapitation 
are summarized in table1. 
 
3.1.2.1 Paper I 
The animals (n=65) were treated with a single injection, into the auditory bulla, of 
either neomycin solution (Neo), or neomycin loaded in 0.5% sodium hyaluronate 
(HYA/Neo), or 0.5% sodium hyaluronate alone (HYA). The ototoxic drug neomycin 
was used as biological marker at a concentration of 15%, 5% and 2%. The animals 
were divided into groups according to the type of treatment and time of collecting the 
cochleae either after 7 or 28 days.  
 
3.1.2.2 Paper II 
Paper II consisted of two experimental series, in the first experimental series, guinea 
pigs (n=21) were used to test the efficiency of three types of chitosans (Ch1, Ch2, and 
Ch3) as drug carrier for the inner ear. The animals were divided into 7 groups. The 
ototoxic drug neomycin was used as biological marker at a concentration of 2%. The 
chitosans and neomycin 2% were used either alone or mixed. The design of the second 
series of experiment was based on the results of the previous experiments. Ch3 was 
chosen for further evaluation of chitosans as a drug carrier into the inner ear. Animals 
(n=14) were divided into 3 groups and Ch3 was used either alone or when loaded with 
neomycin, 2% and 5%.  
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3.1.2.3 Paper III 
In the in vitro experiments, postnatal day 2 rat pups were used for preparation of 
organotypic culture of organ of Corti. These cultures were transfected with 
chitosan/pDNA polyplexes and were processed for immunohistochemistry. For the 
in vivo experiments, adult albino guinea pigs (n=41) were divided into 3 groups; 
chitosan/pDNA polyplexes group (n=15), pDNA group (n=14), and chitosan group 
(n=12). The left cochleae were infused and right cochleae used as contra-lateral control. 
The samples (cochleae) were processed either for immunohisochemistry or PCR. 
 
3.1.2.4 Paper IV 
Right and left cochleae (n=9) of albino guinea pigs used in previous two papers, I and 
II were processed for structural analysis of the round window membrane (RWM) using 
transmission electron microscopy. Normal RWM compared with the membranes 
treated for 7 days with sodium hyaluronate (HYA), Ch1, Ch 2, Ch 3 and saline. RWM 
treated with HYA for 7 days were compared with RWM treated with HYA for 28 days.  
 
Table 1 Summary of the groups, total number of animals and time of decapitation. 
PAPERS GROUPS GUINEA PIG’S DECAPITATION TIME 
1 day 7 days 28 days 
Paper I 
 
HYA/Neo15%  8 4 
HYA/Neo5%  5 0 
HYA/Neo2%  5 5 
Neo15%  8 0 
Neo5%  5 0 
Neo2%  5 0 
HYA alone  9 5 
Saline  6 0 
Paper II 1st part    
Ch1  3 0 
Ch2  3 0 
Ch3  3 0 
Neo2%  3 0 
Ch1/Neo2%  3 0 
Ch2/Neo2%  3 0 
Ch3/Neo2%  3 0 
2nd part  
Ch3/Neo5% 6 0 
Ch3/Neo2% 4 0 
Ch3  4 0 
Paper III Chitosan/pDNA 4 11  
pDNA 4 10  
Chitosan                   4 8  
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3.1.3 Surgical procedures 
Animals were deeply anaesthetized (45-60 minutes) by an intramuscular injection of 
a mixture of Ketalar (ketamine, 40 mg/kg) and Rompun (xylazine, 5mg/kg). The head, 
neck and post-auricular area were shaved and the skin of the areas to be incised and 
over the mid-line of the back (Paper III) was infiltrated s.c. with 0.25% bupivacaine. 
The surgical area was cleaned thoroughly using 10% povidone-iodine solution and 
70% ethanol and draped in sterile fashion. Doxycycline (Doxyferol ® 1 mg/kg i.p) was 
administered as prophylactic antibiotic prior to surgery and on the following day. 
Lubricant eye ointment was applied to prevent corneal ulcers as the blinking reflex 
disappears during anesthesia. The animals kept on a heating pad (Kanthal, type 3654M) 
to maintain a constant core body temperature. At the end of surgery, the animals 
received 5 ml of body warm saline s.c. to prevent dehydration, and buprenorphine 
hydrochloride (Temgesic® 0.05mg/kg) s.c. as long acting analgesic agent. A sterile 
environment was maintained throughout the experiments. The well-being of the 
animals was kept under control and their weight was carefully monitored for a few days 
after surgery. At one, seven or 28 days after surgery, the guinea pigs were anesthetized 
with sodium pentobarbital (90 mg/kg, i.p.) and sacrificed. 
 
3.1.3.1 Middle ear injection procedure (Papers I, II and IV) 
Under an operating microscope, a paracentesis (small opening) was made in the 
tympanic membrane to prevent rupture of the RWM during intratympanic injection as 
the middle ear cavity is an air filled space that might exert pressure on the RWM during 
middle ear filling. Then the middle ear cavity was completely filled (0.15 ml) through a 
fine needle (BD MicrolanceTM 30G; external diameter 0.3 mm) injected into the 
auditory bulla through the skin of the auricle, with either sodium hyaluronate (HYA), 
chitosans or saline. The injections were delivered steadily in order not to cause rupture 
of the tympanic membrane and RWM as well as damaging adjacent structures. The 
surgical procedure was performed on both left and right sides. Left ear was first 
injected and 20 minutes later the right side was injected.  
 
3.1.3.2 Pump insertion procedure (Paper III) 
A post-auricular skin incision was made down to periosteum, which was elevated over 
the bulla then a pocket under the skin on the animals back was made for hosting the 
pump. Under an operating microscope, muscles covering the temporal bone were 
separated and the bulla was exposed. Then a hole in the bulla was made to visualize the 
middle ear cavity, the basal turn of the cochlea, and round window membrane (RWM). 
A small hole was drilled in the basal turn (cochleostomy) 2 mm above the RWM. The 
tip of the prefilled cannula (Scientific Commodities Inc.) with either chitosan, pDNA or 
chitosan/pDNA polyplexes was inserted and secured at the bulla with tissue adhesive 
(Histoacryl, Aesculap AG, Germany). Dental cement (Dentalon plus Heraeus Kuzler, 
Inc. NY, USA) was used to seal the hole in the bulla and secure the cannula in place. 
Miniosmotic pumps (Alzet®mini-osmotic pump, either 1007D; flow rate 0.5µl/h or 
2001D; flow rate 8µl/h;) was filled with 100-200 µl (depending on the duration of 
treatment and model of the pump) of either chitosan, pDNA or chitosan/pDNA 
polyplexes and connected to the cannula and placed in the pocket under the skin on the 
back of the animal between the scapulae. Then the skin was closed in layers. Only the 
left cochleae were infused whereas the right cochleae were used as a control. 
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3.1.4 Tissue preparations 
3.1.4.1 In vivo experiments (Papers I-IV) 
The guinea pigs were deeply anesthetized with an overdose of sodium pentobarbital 
and decapitated. After decapitation, the temporal bones were removed immediately, 
trimmed of excess bone and tissue. The cochleae were dissected out and depending 
on the subsequent procedures the cochleae were either dissected fresh or fixed before 
dissection. For cochlear hair cell counting and immunohistochemistry, the left 
cochleae were immersed in 4% paraformaldehyde. Under the microscope, a small 
opening was made in the apex, and the round window membrane (RWM) was 
perforated to allow the fixative to reach the entire organ of Corti. One hour later the 
samples were transferred to 0.5% paraformaldehyde and stored at 4°C until further 
processing. For the immunohistochemistry, the samples were then decalcified in 
EDTA solution (0.1 M ethylenediaminetetraacetate)  made in 0.1 M phosphate buffer 
for 2 weeks or until the bony capsules were soft enough for the subsequent 
processing.  
For morphological evaluation of the RWM with light and transmission electron 
microscopy, the right cochleae immersed and fixed immediately after dissection in the 
2.5% gluteraldehyde overnight at 4°C. Local perfusion through the RWM step was 
omitted.  
For the PCR analysis, the temporal bones (n=26 samples) were opened and immersed 
in RNA later solution (Qiagen; GmbH, Hilden, Germany) for further dissection. The 
RWM and apical turn were fenestrated. Soft parts of the cochlea including the organ of 
Corti, lateral wall and modiolus were isolated under the microscope and transferred to 
a tube containing 1ml of ice-cold TRIzol (Invitrogen, Carlsbad, CA, USA) and 
homogenized thoroughly with a pestle, and samples were stored overnight at -20°C. 
  
3.1.4.2 In vitro experiments: Organotypic cultures of organ of Corti (Paper III) 
Rat pups were sacrificed and the cochleae were carefully removed from the skull under 
microscope (Zeiss). The cochleae were then placed in phosphate-buffered saline (PBS) 
supplemented with 5.5 µl/ ml of 30% glucose. The stria vascularis, spiral ligament and 
spiral ganglion were carefully pulled away from the organ of Corti. Then 4-5 explants 
per group were transferred to culture inserts (Millicell- CM 0.4 µM 30 mm diameter; 
Millipore)  placed in 6-well plates and cultured in 750 µl DMEM, (Gibco, Invitrogen) 
supplemented with 10 µl/ ml of N1 supplement (Sigma); 5.5 µl/ ml of 30% glucose 
(Sigma) and 100 units/ml penicillin (Gibco, Invitrogen). After 24 hours of incubation at 
37°C and 5% CO2, the cultures were exposed to chitosan/pDNA polyplexes (750 µl) 
for 24 or 48 hours. Following 24 hours incubation with chitosan/pDNA polyplexes, the 
media was replaced by 750 µl of fresh culture medium in the 24 hours exposure group 
and were further incubated for another 24 hours but in the 48 hours exposure group the 
cultures were left all 48 hours with chitosan/pDNA polyplexes. The cultures were 
grouped as follows: (1) cultures exposed to chitosan/pDNA polyplexes for 24 hours, 
and (2) cultures exposed to chitosan/pDNA polyplexes for 48 hours. Control cultures, 
containing only fresh culture media, were run concurrently with the experimental 
cultures. The green fluorescent protein (GFP) expression was measured by recording of 
fluorescence intensity using fluorescence microscopy. The cultures were rinsed in PBS 
and fixed for 1 hour in 4% paraformaldehyde while still on the culture membranes. The 
culture explants were rinsed in PBS, removed from the membranes and processed for 
immunohistochemistry.  
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3.2 HISTOLOGICAL ANALYSIS 
3.2.1 Cochlear hair cell loss counting (Papers I and II) 
The organ of Corti was incubated with phalloidin-TRITC (Sigma-Aldrich) in order to 
stain the filamentous actin and identify the hair cells. After rinsing in PBS, the organ of 
Corti was dissected into approximately 3-mm long pieces and placed on an 8-well 
slide. The hair cell loss was counted using a fluorescence microscope (Zeiss Axioplan). 
The disappearance of stereociliary bundles and scars formation allowed for the 
appropriate quantification of missing hair cells. The percentage of hair cell loss for each 
0.25-mm segment of the cochlea was calculated. 
 
3.2.2 Light and electron microscopy (Papers I, II and IV) 
The right cochleae were rinsed several times with phosphate buffer (PB); osmicated in 
1% osmium tetroxide, and after several rinses with PB, dehydrated with increasing 
concentrations of ethanol. The cochleae were then transferred to propylene oxide, and 
embedded in Agar 100 (Agar 100 Resin kit, Agar Scientific Limited, Essex, England). 
The cochleae were oriented and hardened at 40°C for 24 hours then at 60°C for 
48 hours. After polymerization, the area of the round window niche with the RWM was 
cut out and re-embedded on a blank block of Agar 100. The specimens were sectioned 
at 2.5-µm thickness with an ultrotome (LKB Ultramicrotome system 2128 Ultrotome). 
The sections were mounted on glass slides, stained with toluidine blue and examined 
under a light microscope (Zeiss). Ultra-thin sections (1-µm) were obtained for 
transmission electron microscopy (TEM) with an ultrotome (LKB Cryo Nova), 
mounted on copper grids and stained with alcoholic uranyl acetate and lead citrate and 
then examined with a transmission electron microscope (JEOL 1230) and 
photographed. Images were imported into Adobe Photoshop CS3, and the standard 
methods were used to optimize contrast and brightness.  
 
3.2.3 Immunohistochemistry (Papers I and III) 
In the in vivo experiment, decalcified cochleae were washed with 0.1 M PBS, 
cryoprotected in a 10% and 30% sucrose solution (each for 24 hours) at 4°C, embedded 
in OCT (Tissue-Tek, CA, USA), frozen in super cooled isopentane and stored in the 
freezer. The samples were sectioned (14 µm) using a cryostat (Leica CM 3050S) and 
mounted onto SuperFrost glass slides (Thermo Scientific). The sections were re-
hydrated in PBS and permeabilized with 0.2% Triton X-100 for 10 min. The sections 
were incubated in PBS containing 10% normal goat serum, 5% bovine serum albumin 
(BSA) and 0.3% Triton-X, for one hour at room temperature. The sections were then 
incubated over night with primary antibodies at 4°C (table 2) and after washes with 
PBS; the sections were incubated with secondary antibody for one hour. Finally, 
sections were washed in PBS before mounting in water soluble mounting media 
Mowiol (Calbiochem) and cover slipped. The sections were examined using 
fluorescent microscopy (Zeiss).  
In the in vitro experiment (Paper III), organotypic cultures of organ of Corti were 
blocked for 1 hour with 10% normal goat serum  and 5% BSA with 0.3% Triton X-100 
to block unspecific binding sites, permeabilized with 0.3% Triton X-100 in PBS for 10-
20 min at room temperature. Afterwards cultures were incubated overnight with 
primary antibodies at 4°C, table 2. On the following day, cultures were washed and 
incubated with secondary antibodies. Finally the cultures were stained with DAPI and 
mounted in Mowiol (Calbiochem). The cultures were examined using fluorescent 
microscopy (Zeiss).  
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Table 2 Primary and secondary antibodies used in the papers I and III. 
Antibody Host Concentration Producer Paper 
Primary Anti CD45 Rat 1:100, 500, 1000, 2000 Chemicon I 
Primary Anti PKC β II Rabbit 1:100, 500, 1000, 2000 Sigma-Aldrich I 
Primary Anti myosinVIIa Rabbit 1:1000 Proteus Bioscience III 
Primary Anti GFP Goat 1:500 Abcam III 
Primary Anti GFP Chicken 1:1000 Chemicon III 
2ndry FITC anti rat IgG Goat 1:1000 Sigma-Aldrich I
2ndry TRITC anti rabbit IgG Goat 1:1000 Sigma-Aldrich I
2ndry Alexa 488 anti goat Donkey 1:400 Molecular Probes III 
2ndry Cy3 anti rabbit Goat 1:400 Jackson 
ImmunoResearch 
III 
2ndry FITC anti chicken IgY Goat 1:200 Aveslab III 
 
3.3 MOLECULAR BIOLOGY TECHNIQUES 
 
3.3.1 Total RNA isolation (Paper III) 
The Total RNA was isolated using TRIzol reagent and RNeasy® MinElute Cleanup 
kit (Qiagen). To eliminate possible DNA contamination, samples were subjected to 
on-column DNase digestion with DNase I (Qiagen). Final RNA concentration was 
measured using Invitrogen Qubit.  
 
3.3.2 RT-PCR analysis (Paper III) 
Due to its convenience and high reproducibility, one-step RT-PCR was performed on 
all samples using SuperScript III One-Step Invitrogen kit.The contents of a 10-µl RT-
PCR reaction were 5 µl of 2X Reaction mixture buffer, 1µl template RNA, 0.4 µl of 
sense and anti-sense primers (10 µM), 2.8 µl RNase free water and 0.4 µl of 
SuperScriptIII RT/ Plat TaqMix. Optimal annealing temperature and PCR cycle 
number for the primers were determined with a gradient thermocycler (PTC-200, MJ 
research).The reverse transcription (cDNA) synthesis was performed in one cycle of 
50°C for 30min. The PCR amplification consisted of 30 cycles of 15 seconds 
denaturation at 94°C, 30 seconds at 59°C annealing temperature and one minute of 
extension at 68°C. A final single extension cycle of 68°C for 5 minutes was added at 
the end. No-RT controls were run for each sample by replacing the RT/ TaqMix with 
a DNA polymerase (Invitrogen). RT-PCR products were run on 2% agarose gels 
containing ethidium bromide (0.5µg/ml) and visualized in ultraviolet light. A One-Step 
RT-PCR with GAPDH specific primers was performed to verify RNA integrity. The 
cDNA synthesis was performed in one cycle of 55°C for 30 min. The PCR 
amplification consisted of 33 cycles at of 15 seconds denaturation at 94°C, 30 seconds 
at 58°C annealing temperature and one minute of extension at 68°C. A final single 
extension cycle of 68°C for 5 minutes was added at the end. The content in the reaction 
tubes was as described above. The primers used were designed using online free 
software Primer3 [172] and were as follows: 
GFP forward primer (GCCCGAAGGTTATGTACAGC) and reverse primer 
(GTCCCAGAATGTTGCCATCT).  
GAPDH forward primer (GCCAACATCAAGTGGGGTGATG) and reverse primer 
(GTCTTCTGGGTGGCAGTGATG). 
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3.4 MATERIALS 
 
3.4.1 Neomycin (Papers I and II) 
The ototoxic drug neomycin trisulfate salt hydrate (Sigma-Aldrich) was used as 
an indicator for the RWM passage.  
 
3.4.2 Sodium hyaluronate, HYA (Papers I and IV) 
Sodium hyaluronate, HYA 0.5% was a kind gift from Advanced Medical Optics, 
Uppsala, Sweden.  
 
3.4.2.1 Preparation of HYA/neomycin formulation (Paper I)  
Three concentrations of neomycin were used with 0.5% HYA. A stock solution of 1% 
(w/w) HYA was prepared in PBS and was then autoclaved. Parallel to this, a 30% 
(w/w) neomycin stock solution was prepared. This solution was not autoclaved, as the 
heat would degrade the neomycin. However, as neomycin is antibacterial in itself 
bacterial growth was efficiently prevented. The final mixtures where then composed 
from 50% HYA solution together with 50%, 16.67% or 6.67%  neomycin stock 
solution to give final neomycin concentrations of 150 mg/ml, 50 mg/ml, and 20 mg/ml, 
respectively. The samples were adjusted to final volume with PBS. Additionally, 
a 0.5% reference HYA solution was prepared from 50% HYA stock solution and 50% 
PBS. Preparation of the neomycin solutions was performed in a similar manner. A 30% 
neomycin stock solution was prepared, which was then used for proportional mixing 
with PBS to yield neomycin solutions at final concentrations of 15%, 5%, and 2%. 
 
3.4.3 Chitosans (Papers II and IV) 
In paper II and IV we used three different types of chitosans and in paper III a self-
branched and trisaccharide-substituted chitosan oligomer (SB-TCO) was used (table 3). 
Chitosan 1 (Ch1) was a completely deacetylated polymer with high charge density and 
low molecular weight. Chitosan 2 (Ch2) represents a conventional polymer with middle 
molecular weight. Chitosan 3 (Ch3) was an oligomeric glycosylated chitosan which 
was completely soluble at neutral pH. All chitosans were prepared by heterogeneous 
de-N-acetylation of chitin and converted to hydrochloride (HCl) salts. Ch1 was 
prepared by nitrous acid depolymerization of fully de-N-acetylated chitosan. Ch2 was a 
direct product of the de-N-acetylation. The glycosylated Ch3 and SB-TCO were 
prepared by controlled nitrous acid depolymerization of fully de-N-acetylated chitosan 
followed by self branching and substitution with the trimer 2 acetamido-2-deoxy-D-glu
-copyranosyl-β−(1-4) 2-acetamido-2-deoxy-D-glucopyranosyl-β-(1-4)-2,5-anhydro-D 
mannofuranose (A-A-M) as described previously [152]. All samples were dissolved in 
Milli-Q water (5-7 mg/ml) and filtered through 0.22 µm syringe filter (Millipore). The 
column used was TSK 3000, and sample was eluted with 0.2 M ammonium acetate 
(pH 4.5) at a flow rate of 0.5 ml/min. The molecular weight (Mw) and molecular 
weight distribution (Mn) were analyzed by Size-Exclusion Chromatography with 
refractive index (RI) and a Multi-Angle Laser Light Scattering detector (SEC-
MALLS). The degree of substitution of A-A-M was determined by nuclear magnetic 
resonance spectroscopy 1H NMR. 
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Table 3 Characteristics of the chitosans used in the papers II, III and IV. 
Sample FAa Mnb Mwc PDId d.s. A-A-Me 
Chitosan 1 (Ch1) <0.002 17,600 32,900 1.87 0 
Chitosan 2 (Ch2) 0.15 64,000 148,000 2.31 0 
Chitosan 3 (Ch3) <0.002 8600 11,800 1.37 7.3 
SB-TCO <0.002 13 700 22 000 1.61 7.3 
(a) Fraction of acetylated units. (b) Molecular weight. (c) Molecular weight distribution. 
(d) Polydispersity index. (e) Degree of substitution. 
 
 
3.4.3.1 Preparation of chitosan/neomycin formulation (Paper II) 
Chitosan-HCl salts were dissolved in Milli-Q grade water and the ionic strength was 
adjusted to 0.15 M by addition of NaCl. The pH of the chitosan solution (5 mg/ml) was 
carefully adjusted to 6.0 and the solutions were filtered through 0.22-µm filter. Four 
percent and 10% w/v stock neomycin solutions were prepared in 20 mM 
N-morpholino-ethanesulfonic acid (MES, gma M3058) buffer pH 6.2, supplemented by 
270 mM mannitol to retain osmomolarity. Both stock solutions were filtered through 
a 0.22-µm filter (Millipore). The final formulations were then prepared by mixing equal 
amounts of chitosan solutions and neomycin stock solutions (4 and 10%) so that the 
final concentration of chitosan was 2.5 mg/ml and the concentrations of loaded 
neomycin were 20 mg/ml (2%) and 50 mg/ml (5%). 
 
3.4.3.2 Preparation of chitosan/DNA polyplexes (Paper III) 
Polyplexes of chitosan with amino/phosphate (A/P) ratios of 30:1and pDNA were 
prepared by the self-assembly method. For the in vitro experiments, the polyplexes 
were prepared as described above with a pDNA concentration of 13.3 µg/ml. The 
polyplexes were further diluted 1:2 in OptiMEM I (Gibco, Invitrogen) supplemented 
with 270 mM mannitol and 20 mM HEPES to adjust the osmomolarity and pH of the 
formulation. For the in vivo experiments, an aliquot of 0.264 ml of pDNA 
(0.5 mg/ml) was diluted in deionized water (MQ-Millipore) and a required amount of 
sterile filtered chitosan stock solution in MQ-grade water (4 mg/ml) was added during 
intense stirring on a vortex mixer (1200 rpm, Heidolph REAX 2000, Kebo Lab, 
Sweden), yielding a pDNA concentration of 110 µg/ml.  The size of chitosan/pDNA 
polyplexes, expressed as mean hydrodynamic diameter (z-average), was 128 ± 7 nm 
as determined by dynamic light scattering on a Nanosizer ZS (Malvern Instr., 
Malvern, UK).  
 
3.4.4 Plasmid DNA (Paper III) 
Reporter plasmid (gWizTMGFP) containing a cytomegalovirus promoter (CMV) and 
green fluorescent protein (GFP) was purchased from Aldevron, Fargo, ND, USA. 
 
3.4.5 Mini-osmotic pumps (Paper III) 
Alzet®mini-osmotic pump 1007D; flow rate 0.5µl/h; release duration of one week and 
pump 2001D; flow rate 8µl/h; release duration of one day (ALZET Osmotic Pumps, 
Cupertino, CA and Scanbur AB, Stockholm-Sweden) were used.  
 
3.4.6 Micro-cannula (Paper III) 
A 7.5 cm vinyl tubing (Sscientific Commodities Inc., AZ, USA) was used to make 
handmade cannula. A 7 mm piece of polyimide tubing (MicroLumen, FL, USA), was 
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placed 1-2 mm into the end of the vinyl tubing. The two component silicone glue 
(MDX 4-4210, Dow Corning Corp., MI, USA) ten parts base and one part of curing 
agent were mixed thoroughly. With a fine probe the silicone was put at the opening and 
allowed to flow into the vinyl tube. Approximately 3.75 mm of the polyamide 
protruded out of vinyl tube. On the part outside the polyamide tubing, a silicone ball 
was placed leaving a 0.5 mm tip on the micro-cannula to be inserted to the 
scala tympani. This silicone ball is important to close the cochleostomy and prevent 
leakage of perilymph. Then the cannulae were allowed to dry overnight and their 
patency was checked. Prior to use, the cannulae sterilized by soaking overnight in 
70% ethanol [128,173]. 
 
3.4.7 Statistical analysis  
Statistical analysis was made with the software SigmaStat 9.0 for Windows. The data 
were analyzed with the Wilcoxon paired 2-sample test, Mann-Whitney U test, and 
Kruskal Wallis variance. Descriptive statistics representing mean and standard 
deviation have been calculated for the hair cell loss, and the RWM thickness. The level 
of significant statistical difference was set at p < 0.05. 
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4 RESULTS 
4.1 COCHLEAR HAIR CELL LOSS (PAPERS I AND II) 
The ototoxic drug neomycin, well known to cause rapid degeneration of the cochlear 
hair cells, was used as a biological trace marker for RWM passage. It was expected that 
once released from the loading carriers (sodium hyaluronate and chitosans) and passed 
across the RWM, the neomycin would cause loss of outer hair cells (OHCs) and inner 
hair cells (IHCs). It was assumed that the amount of neomycin that passed through the 
RWM was correlated to the resulting loss of hair cells i.e. the hair cell loss was 
dependent on the concentration of neomycin released and the amount that diffused 
across the RWM. Sodium hyaluronate (HYA) was loaded with three different 
concentrations of neomycin, 2%, 5% and 15% and three structurally different chitosans 
were loaded with neomycin 2% and 5% in order to observe a dynamic range of effect 
throughout the length of cochlea. As illustrated by the ototoxic effect on the cochlear 
hair cells, neomycin was readily delivered from the HYA and chitosans, and 
transported into the cochlea. In contrast, the HYA and chitosans themselves caused no 
damage to the hair cells.  
 
4.1.1 Hair cell loss following HYA/neomycin exposure 
Loss of OHCs in all three rows as well as IHC loss was seen 7 days after treatment, 
even at the lowest concentration of neomycin tested (see Fig.1 and 2 in Paper I). In 
general, for comparable dose groups there were small differences in the toxic effect. 
However, the differences in hair cell loss among the basal regions of Neo15% and 
HYA/Neo15% groups and apical regions of Neo2% and HYA/Neo2% groups were 
statistically significant (p<0.05). 
 
4.1.2 Hair cell loss following chitosans/neomycin exposure 
In the first series of experiments, neomycin at a 2% concentration was loaded in three 
different chitosan formulations. Although the differences between the three types of 
chitosan in releasing neomycin were not statistically significant (P ≥ 0.05), Ch3 seemed 
slightly more efficient in releasing neomycin (see Fig.1 in Paper II). To facilitate 
comparisons, only data from the counts of the second row OHC 2 were shown. In the 
groups treated with neomycin 2% whether alone or when loaded in chitosans, the hair 
cell loss was seen in the basal region sparing the apical regions. In contrast, the 
chitosans alone had no damaging effect on the hair cells.  
The glycosylated chitosan, Ch3 loaded with Neo2% and Neo5% in order to see if 
an increase in the neomycin concentration would produce more hair cell loss along the 
length of organ of Corti, i.e. to increase the dynamic range of the model. The 
differences in cochlear hair cells loss between the treatment groups Ch3/Neo5% and 
Ch3 (see Fig. 4 in Paper II) were statistically significant (P ≤ 0.05). In the 
Ch3/Neo5% group there was more cochlear hair cells loss along the length of organ of 
Corti than the Ch3/Neo2% group; however, the differences were not statistically 
significant (P ≥ 0.05).  
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4.2 RWM THICKNESS (PAPERS I AND II) 
To study the effects of HYA and chitosans with neomycin on the RWM, the exposed 
tissue was sectioned and the RWM thickness was measured. The thickness of the 
RWM in normal, unexposed control ears were close to 10 µm (see Fig. 5 in Paper I).  
 
4.2.1 RWM thickness following HYA/neomycin exposure 
There was a swelling of the RWM at day 7 after administration in all groups receiving 
either neomycin solution or HYA with neomycin (see Fig. 5 and 6 in Paper I). In the 
HYA/Neo15% group the thickness of the RWM had increased significantly to 
(25.2 µm ± 11.7). At 28 days the thickness returned to normal (13.3 µm ±1.9). In the 
HYA/Neo2% group the RWM increased to (16.1 µm ± 2.7) but, again the thickness 
was normalized at day 28 (12.1 µm ± 0.5). In the Neo15% group at 7 days post 
treatment, the thickness of the RWM had increased to (16.6 µm ± 0.1). Interestingly, 
also when the HYA alone was administered, the thickness of the RWM showed 
a significant increase to (19.7 µm ± 4.5). At day 28, the thickness of the RWM had 
returned to normal values (11.8 µm ± 0.9).  
 
4.2.1.1 Inflammatory marker 
At the light microscopic level there was no sign of any inflammatory processes in any 
of the animals. To further investigate whether the surgical procedures and the HYA 
administration caused any signs of inflammatory processes, sections from the RWM of 
two guinea pigs receiving the HYA alone were processed for immunohistochemistry, 
table 2. However, no positive immunostaining signals were detected from the exposed 
(HYA) and the non-exposed RWM.  
 
4.2.2 RWM thickness following chitosans/neomycin 
exposure 
At day 7 after administering the neomycin solution, chitosan/neomycin, and 
interestingly also the free chitosans, the RWM showed an increase in thickness 
(see Fig. 2 and 5 in Paper II). The Ch2/Neo2% group (24.2 µm ± 4.9) and Ch2 group 
(23.2 µm ± 5.1) were associated with the greatest increase in RWM thickness. The 
difference between the treatment groups Ch2/Neo2% and Ch3/Neo2% (17.4 µm ± 2.3) 
was statistically significant (P ≤ 0.05). The difference between the Ch3/Neo5% 
(15.9 µm ±1.5) and Ch3/Neo2% (17.4 µm ± 2.3) group was not significant.  
 
4.2.3 RWM thickness following saline exposure 
These membranes showed a slight thickening, (12.0 µm ± 0.6) when compared with 
unexposed RWM (see Fig. 5 in Paper I).  
 
4.3 RWM MORPHOLOGY (PAPER IV) 
To study the effects of HYA and chitosans (Ch1-3) on the ultrastructure of the RWM, 
nine cochleae were prepared for transmission electron microscopy (TEM). Sections of 
non-exposed membranes, membranes exposed to HYA for 7 and 28 days, membranes 
exposed to Ch1-3 and saline for 7 days were analyzed with TEM. 
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4.3.1 Normal RWM morphology 
The RWM consists of three layers (see Fig 2 in Paper IV): an outer epithelium, 
connective tissue, and an inner epithelium. 
Outer Epithelium is a single layer of epithelial cells. The epithelial cells have rounded 
nuclei located centrally within the cytoplasm. On the free surfaces of the cells there are 
short microvilli. The cytoplasm contains mitochondria and Golgi apparatus. On their 
lateral walls, the epithelial cells are interdigitating with each other and there are tight 
junctions.  
Connective Tissue layer constitutes bulk of the RWM. Collagen fibers together with 
fibroblasts, elastic fibers and ground substance make up the connective tissue core. It 
contains blood vessels which run from the edges to the center beneath the epithelial 
layer.  
Inner Epithelium consists of a single layer of epithelial cells with long lateral 
extensions. The cells junctions are loose and the space between the cells is wide. Unlike 
the outer epithelial cells, the nuclei are elongated; the cytoplasms contain pinocytotic 
vesicles and few organelles, and have no microvilli.  
 
4.3.2 RWM morphology following HYA and chitosan 
exposure  
At day 7 after middle ear injection of HYA, chitosans and saline, the membranes were 
thickened. HYA, Ch1 and Ch3 had comparable effects on the thickness of the RWM 
while Ch2 induced greater thickening. RWM exposed to saline showed a slight increase 
in RWM thickness (see Fig. 3 in Paper IV). The thickening was confined to the 
connective tissue layer due to edema which resulted in widening of the extracellular 
spaces.  
In the HYA and chitosans exposed RWM, the epithelial cells of the outer epithelial 
layer became larger in size and swollen. Their nuclei appeared swollen and the 
cytoplasm showed numerous intracellular vacuoles and enlarged intercellular spaces. 
Twenty-eight days after RWM administration, the RWM started to regain its normal 
characteristic structure and thickness. However, the epithelial cells looked larger than 
the normal ones and the connective tissue layer contained more collagen fibers and 
elastic fibers that were more pronounced close to the inner layer 
(see Fig. 4 in Paper IV). As an interesting finding, the membrane exposed to HYA for 
28 days, showed opening up of the tight junction between the epithelial cells 
(see Fig. 5 in Paper IV).  
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4.4 TRANSFECTION OF THE INNER EAR (PAPER III)  
The feasibility of chitosan mediated gene delivery tested both in vitro and in vivo and 
the samples were processed for immunohistochemistry and PCR.  
 
4.4.1 In vitro results 
Organotypic cultures of organ of Corti, prepared from postnatal day 2 rats, were 
incubated with chitosan/pDNA polyplexes for 24 or 48 hours (see Fig. 2 in Paper III). 
Immunostaining of the cultures revealed GFP expression in cultures treated with 
chitosan/pDNA polyplexes which was not observed in control cultures. The cells were 
not transfected equally and expression was observed in some regions of the cultures. 
Additionally, more transfected cells were observed in the cultures incubated for 
48 hours compared to cultures incubated for 24 hours.  
 
4.4.2 In vivo results  
We tested the feasibility of chitosan mediated gene delivery in the guinea pig following 
cochlear infusion using osmotic pumps. The spiral ganglion and organ of Corti were 
examined for signs of GFP expression in treated samples and compared with 
corresponding areas in control samples with and without using primary antibodies. 
There were no differences between sections treated with chitosan/pDNA polyplexes, 
pDNA, and chitosan alone (see Fig. 3 in Paper III).  
Several runs of RT-PCR were performed on the samples treated with chitosan /pDNA 
polyplexes, pDNA and chitosan alone (see Fig. 4 in Paper III). The results showed 
varying degree of GFP expression as four out of 9 samples treated with the 
chitosan/pDNA polyplexes showed positive transfection. The sample that showed the 
most intense band originated from an animal receiving chitosan/pDNA polyplexes for 
7 days (see Fig.4 A, lane 6 in Paper III). However, the overall transfection pattern was 
inconsistent, as the replicates in the chitosan/pDNA polyplexes groups and pDNA 
groups for either one or seven days showed varying degree of transfection.  
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5 DISCUSSION 
One of the clinically most interesting and relatively non-invasive potential pathways for 
the inner ear drug administration is the round window membrane (RWM). The RWM is 
surgically accessible and offers, at least theoretically where the drug (loaded in 
a polymer or a gel) applied to the RWM, direct access to the perilymphatic 
compartment of the cochlea and thus to the cells of the hearing organ without damaging 
the cochlea [174]. Intratympanic drug application is a method of introducing substances 
into the inner ear without damaging the cochlea by perfusion of the middle ear cavity 
with therapeutic agents through the tympanic membrane [99]. The intratympanic drug 
application depends on passage of the therapeutic agents through the RWM into scala 
tympani. The RWM approach for drug delivery is known to lead to much higher 
intracochlear concentrations than systemic drug delivery [91] hence promoting optimal 
outcomes in the cochlea while avoiding side effects in other organs. A variety of 
compounds of interest have been demonstrated to diffuse across the RWM in animals, 
for example antibiotics, dexamethasone, liposomal and adenoviral gene transfer 
vectors, and neurotrophins [1-4,45,61-63,98,175]. Since it was started for treatment of 
Meniere's disease with streptomycin by Schuknecht in 1956 [31], intratympanic 
pharmacotherapy is still in use for delivery of gentamicin for the treatment of Ménière's 
disease and steroids for the treatment of sudden sensorineural hearing loss and tinnitus 
[7-11]. In the future, cochlear gene therapy and stem cell transplants will likely require 
delivery of drugs and growth factors into the inner ear [135-137]. 
To test the suitability of the RWM as a site for inner ear drug delivery, we used two 
different types of drug vehicles, sodium hyaluronate (HYA) and chitosans. The 
vehicles were loaded with the ototoxic drug neomycin as a pharmacological “tracer” in 
guinea pigs model to show whether the drug carrier can release the drug and cause 
cochlear hair cell loss and how the vehicles affect the morphology of the RWM. The 
pattern of ototoxicity in the guinea pig resembles that in humans [176]. The use of 
a slow-releasing vehicle injected into to the middle ear cavity is considered as 
a promising candidate for clinical pharmacological therapy of inner ear disorders. This 
type of drug administration may be especially important in searching for strategies to 
prevent hearing loss in patients receiving systemic treatment with a highly ototoxic 
drug. The advantages in such cases are to avoid drug interaction at the systemic level. 
In addition to pharmacological substances, it is of interest to explore the use of gene 
transfection for inner ear treatment. Again, for a possible clinical use, RWM 
administration seems most feasible.  
The literature shows few studies comparing an i.v. route for drug administration with 
intratympanic administration. However, paper I and II were the first studies comparing 
two different modes of local administration (fluid-based and vehicle-based) to the inner 
ear and reflections concerning differences between the two modes of topical 
administration. In paper I and II, the ototoxic effects of neomycin loaded in HYA and 
chitosans were quantified as the percentage of hair cell loss along the length of the 
cochlea and compared with that induced by free neomycin solution. In both types of 
topical administration, neomycin exerted varying damage to the cochlear hair cells with 
greatest hair cell loss in the basal regions of the organ of Corti. Neomycin was 
successfully released from both HYA and chitosans which then diffused into the inner 
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ear as evidenced by loss of hair cell in a degree depending on the concentrations of 
neomycin loaded in the HYA and chitosans. 
Main limitation of intratympanic injection is that many variables exist that may alter the 
amount of the drug that comes into contact with RWM and concentration in the 
perilymph. This mode of entry depends on simple diffusion to pass drug from the 
middle ear cavity to the inner ear, and once in the scala tympani, the only mode of 
distribution is simple diffusion in a fluid space. Therefore, access to the apical regions 
of the scala tympani can be limited. RWM drug delivery often leads to a severe base-
apex concentration gradient, making it difficult to predict the amount of drug that will 
be available for cells in different turns of cochlea. The assumption that drugs applied to 
the RWM may have access to all turns of the cochlea may be valid for some rodents 
[63,177-180] but is not likely to be true for the human. The membrane is a major 
absorption site but blood vessels, lymphatics and annular ligament of the oval window 
also play a role. Beside the presence of fibro-fatty tissue in the RW niche which gives 
variation in the rate of absorption. Uncontrolled duration of the contact with RWM and 
clearance of the drug from middle ear either by drainage through Eustachian tube or by 
absorption through the middle ear mucosa need to be considered when extrapolating 
results from preclinical studies for planning clinical studies with intratympanic drug 
delivery to the inner ear. 
 
5.1 COCHLEAR HAIR CELL LOSS (PAPERS I AND II) 
In paper I we tested the effect of three different concentrations of neomycin in a sodium 
hyaluronate (HYA) vehicle versus neomycin (see Fig. 1 and 2 in Paper I). Controls 
consisted of HYA alone or saline. Our aim was to evaluate HYA as a carrier to aid in 
drug delivery to the inner ear. Seven days after middle ear injection, cochlear hair cell 
loss was seen in a dose-dependent way, strongly indicating that neomycin was released 
from the HYA and transported to the inner ear and thereby inducing loss of cochlear 
hair cells. Its speculated that HYA can modulate the RWM permeability [181] but our 
findings (Paper I) provides no indication that this occurs to a significant degree and we 
have not found the support for a change of RWM permeability induced by HYA. 
Similarly, in paper II three different types of chitosans (see. Fig. 1 and 4 in Paper II) 
were loaded with neomycin, the data showed that neomycin applied with or without 
chitosans caused very similar effects and gave no indication that drug entered 
perilymph more easily with chitosans present. One question is whether treatment of the 
RWM with HYA and chitosan increases permeability or not. Neomycin applied with 
HYA and chitosans was not delivered more easily to the inner ear than neomycin in 
solution. There was neither a difference in total hair cell loss nor a difference in the 
apical versus basal regions for the same neomycin concentration. However, the main 
points are that HYA and chitosans indeed cause no detrimental effects and that they do 
release the test drug. Hair cell loss was as an endpoint for toxic effect of neomycin on 
the inner ear. We used the ototoxic drug neomycin as a “bio-indicator” for drug release 
to show whether the drug carrier can release the drug to pass through the RWM and 
cause cochlear hair cell loss. The effect of the tracer drug per se was not one of 
objectives to assess as it is well known that neomycin is a potent ototoxic drug once in 
the inner ear fluids. One cannot exclude that the situation may be different with other 
compounds. The HYA and chitosans themselves exerted no toxic effect on hair cells.  
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In animals treated with Neo15% and HYA/Neo15%, the ototoxic effect was severe and 
seen throughout the whole length of the organ of Corti (see Fig. 1 in Paper I). At the 
highest concentration of neomycin tested (15% in paper I) the ototoxic effect was 
slightly greater in the neomycin solution group as compared to the HYA group. At this 
dose level the variability of hair cell loss was greatest in the HYA group.  
Provided that there was a correlation between hair cell loss and amount of neomycin 
reaching the inner ear compartments, this finding reflects that the solution vehicle was 
more efficient to transport neomycin across the RWM at a very high concentration of 
neomycin. In contrast, by lowering the dose of neomycin no enhanced ototoxic effect 
was seen in the solution groups. In guinea pigs, the bone of the cochlear apex is thinner 
than that in the basal turn [182]. Thus, the high apical concentrations might be 
consistent with the substance entering the perilymph through the thin bony otic capsule. 
As the bone surrounding the human cochlea is much thicker; it is expect that high drug 
levels exist in the basal turn and very low levels in apical regions [182]. However, it is 
also possible that drug permeability through the bone may be changed in pathologic 
lesions affecting the otic capsule, such as otosclerosis [183].  
By lowering the concentration of neomycin no enhanced ototoxic effect was seen in the 
apical region. Neomycin destroys the OHC as well as IHC and the supporting cells of 
the organ of Corti in a dose dependent manner [176]. The toxicity may be a dose 
dependent phenomenon in the inner ear with higher levels resulting in profound hair 
cell loss. HYA/Neo5%, HYA/Neo2%, Ch1/Neo2%, Ch2/Neo2%, Ch3/Neo2%, 
Ch3/Neo5%, Neo5% and Neo2% produced a stepladder effect with a greater loss of 
OHCs in the basal turn of the cochlea compared to the apical parts.  
Despite different properties, the three tested chitosans showed comparable effects on 
the delivery of neomycin (see Fig. 1 and 4 in Paper II). The differences in cochlear hair 
cells loss, between the treatment groups Ch3/Neo5% and Ch3 were statistically 
significant. In the group received Ch3/Neo5%, there were more cochlear hair cells loss 
along the length of organ of Corti than the group received Ch3/Neo2%, showing that 
increased neomycin concentration, changed the dynamic range of ototoxic effect of 
neomycin. However, the differences in cochlear hair cells loss between Ch3/Neo5% 
and Ch3/Neo2% groups were not statistically significant. The difference between loss 
of OHCs in the basal parts and the apical parts, suggests a gradient for neomycin along 
the cochlear compartments after RWM administration. This demonstrates that 
substances entering the perilymph only move slowly along the perilymphatic spaces 
and a higher absorption rate would present the basal turn of the cochlea with a higher 
level of ototoxic drug. Longitudinal perilymph flow has a marked influence on the 
amount of a substance reaching the second turn [184]. It cannot be excluded that the 
pharmacokinetics of two types of topical administration might differ and thereby the 
induction of cell death pathways. A number of studies investigating the entry, 
distribution and quantification of tracers and drugs into the inner ear have determined 
that a substantial concentration gradient is established with highest concentrations at the 
basal turn and low concentrations at the apex in a way the concentration near the RWM 
remained higher than that of apical turns. This has obviously important implications for 
the clinical use of a RWM approach for drug delivery. [100,184-189]. Noushi and co-
workers suggest suitability of the RWM as a delivery site for the hair cells and SGN 
protection despite the concentration gradients [63].  
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5.2 RWM THICKNESS (PAPERS I AND II) 
The importance of the RWM in drug delivery into the inner ear led us to investigate the 
RWM thickness after application of sodium hyaluronate (HYA) and chitosans. The 
thickness of the midportion of the RWM was calculated 7 or 28 (Paper I only) days 
after topical administration. All groups showed an increase in RWM thickness 
(see Fig. 3-5 in Paper I and Fig. 2, 3 and 5 in Paper II). Even saline 0.9%, HYA and 
chitosan without any loaded neomycin caused an increase in the thickness of the RWM. 
The change in thickness was mostly due to edema in the middle connective tissue layer. 
The thickness of RWM exposed to both the HYA and chitosan loading neomycin, was 
found to be depending on the concentration of neomycin and duration of the follow-up 
period. 
Greatest effects on the thickness occurred in the HYA/Neo15% group, increasing from 
normal 10 µm to 25 µm and at 28 days the RWM thickness decreased to 13µm 
(see Fig.6 in Paper I). One might question if the RWM react to any solution or vehicle 
instilled into the middle ear. The question arises because the swelling of the RWM 
appears related to the injection of "anything" into the middle ear. A single injection of 
HYA alone and chitosans alone caused the RWM to swell. The thickening of the RWM 
caused by the HYA alone and HYA/Neo, disappeared within 28 days so it was 
concluded that HYA causes no permanent structural damage to the RWM  and it is 
a safe vehicle for drugs aimed to pass into the inner ear through the RWM. This was 
further supported by the apparent lack of inflammatory processes. This finding is in 
accordance with a number of earlier studies showing that HYA instilled into the middle 
ear do not produce signs of cochlear toxicity [181,190-193]. Biodegradability of HYA 
depends on the viscosity and concentration of the HYA used. Engström et al. have 
experimentally shown that most of the injected HYA into the middle ear cavity will be 
eliminated after 28 days [158].  
In paper II, all tested chitosans caused the RWM to swell but Ch2 had the greatest 
effect (see Fig. 2 and 3 in Paper II). Compared to Ch3, Ch1 and Ch2 possessed higher 
molecular weights and lower solubility at physiological conditions which may have 
delayed the degradation. The saline 0.9% exposed membranes showed 
a non-significant thickening compared with the unexposed control membranes. There 
are earlier studies showing that even an injection of saline induces a swelling of the 
RWM when unexposed and saline exposed membranes were compared. Any local 
application initiates a certain swelling of the RWM and as the middle ear is normally an 
air-filled cavity, exposure to saline or any other vehicle is unnatura [58,65]. HYA is not 
permeable through the RWM and therefore most likely acts through an osmotic effect 
on the perilymph [194]. There is possibility that some uncontrolled aspect of the 
injected solution might have influenced the RWM thickness. So we cannot fully 
exclude the possibility that an ingredient in the HYA and chitosans could influence on 
RWM thickness or cause a difference in thickness as an osmotic effect but exploring 
this issue further was beyond the scope of this thesis. The implication of swelling to the 
passage of drugs is not clear. It could be speculated that the swelling, despite making 
the membrane thicker, actually makes the tissue more loose and permeable thus 
facilitating drug entry into the inner ear fluids. 
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5.3 RWM MORPHOLOGY (PAPER IV) 
In paper IV we wanted to investigate how the carriers influence the structural 
components of the RWM in guinea pigs using transmission electron microscopy after 
instillation of sodium hyaluronate (HYA), three different chitosans and saline into the 
middle ear cavity. In general, the RWM of the human and other species are similar in 
that they are three-layered membrane [41,195]. But the RWM of the rodents is much 
thinner than RWM in the human [41,44,55]. Our findings (see Fig. 2 in Paper IV) have 
confirmed the normal structure of the RWM described in the literatures [43-45]. The 
presence of microvilli is interesting in that they increase the surface area of the RWM 
and should promote drug uptake. Toward the inner cell layer, the number of fibroblasts, 
collagen fibers and elastic fiber increase [51,60]. It may be assumed that the area of 
connective tissue layer close to the inner epithelia layer could be associated with the 
perilymph wave and thus involve elasticity. The high density of elastic fibers toward 
the inner epithelial layer suggested that they may participate in the barrier function of 
the RWM [60]. The discontinuity in the inner cell layer suggests that the perilymph 
may communicate directly with the connective tissue layer [44,45,60].  
The HYA, chitosan, and saline-exposed membranes were thickened when compared 
with non-exposed membranes (see Fig.3 in Paper IV) but there were no signs of 
pathological and inflammatory process which are associated with exposure of RWM to 
a notorious agent [58,85]. The difference in the HYA, chitosans and saline exposed 
RWM thickness was due to the increase in the connective tissue layer. Changes were 
about the same following single exposures of HYA and Ch1 and Ch3, except for 
membranes exposed to Ch2 which had the greatest effect on the RWM thickness. The 
high molecular weight of Ch2 might have role in this effect. Although it is reported that 
chitosans can open the tight junctions between the epithelial cells [149,164,170] we 
could not observe such finding in the chitosans treated RWM. This finding was seen in 
the membrane exposed to HYA for 28 days as an odd finding (see Fig.5 in Paper IV).  
The saline exposed RWM slightly increased in the thickness if compared to normal 
membrane. This might be due to effect of the physical manipulation of the RWM 
and/or osmotic effect of the ionic composition of the saline. 
The important finding was that the increase in the thickness of the RWM exposed to 
HYA after 7 days restored to normal level after 28 days (see Fig. 4 in Paper IV). This 
finding implies that the HYA caused no permanent changes in the structure of the 
RWM. Since the HYA and chitosans have comparable effect on the RWM, it is 
expected that the thickness of the RWM exposed to chitosans also return to normal 
values after 28 days of exposure. Earlier reports suggested that no histologic cochlear 
damages and no permanent structural damage to the RWM were seen after 
administration of high concentrations of HYA and chitosan into the middle ear 
[105,181,193,194,196-199]. In the early stages of an experimentally induced serous 
otitis media in guinea pigs, Nomura and Sahni and co-workers have reported features 
of inflammatory reaction in the RWM such as edema of the connective layer with 
dissociated collagen fibers, elastic fibers and fibroblasts. In the later stages of the 
inflammation there was more edema in such way that the collagen fibers, elastic fibers, 
and fibroblasts were existed independently and it was not possible to identify different 
cell organelles. Twenty eight days after application of HYA, the collagen fibers, elastic 
fibers and fibroblasts did not show the pathological changes seen after inflammatory 
reaction in the RWM [36,51]. However, since it has been reported earlier 
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[44,45,59,60,200] that during inflammatory conditions of the middle ear cavity and 
manipulations of the RWM initially there will be an increase in RWM permeability due 
to increase in its thickness, later thickening and scarring might affect the permeability 
of the RWM, this is an important point to investigate since it affects the passage of drug 
in the subsequent drug applications. Thus further studies should investigate the 
impaction of the structural changes of RWM on the passage of drug loaded in the HYA 
or chitosans. 
 
5.4 CHITOSAN AS A GENE CARRIER INTO THE COCHLEA (PAPER III) 
In paper III, we investigated the efficiency of chitosan as a vehicle for gene delivery 
into the cells of the inner ear both in vitro (see Fig. 2 in Paper III) and in vivo 
(see Fig. 3 in Paper III). In the in vitro experiments, both the IHCs and the OHCs 
displayed expression confirming successful pDNA delivery in vitro. However, not all 
cells were transfected equally and they showed different GFP intensity in cultures 
incubated with the transfection medium for 48 hours compared to cultures exposed for 
24 hours. In the 24- hour group, the chitosan/pDNA polyplexes was replaced by fresh 
culture medium after 24 hours and the tissue was further incubated for another 24 hours 
whereas in the 48-hour exposure group the cultures were incubated with the 
chitosan/pDNA polyplexes for the entire time period. Thus the growing time was the 
same in all cultures (48 hours). The results suggest that the prolonged incubation time 
led to increased cellular uptake of chitosan/pDNA polyplexes. However, it is possible 
that with the prolonged incubation time (48 hours) more time had elapsed for protein 
translation leading to increased expression.  
The in vivo transfection in the inner ear did not show good correlation with the in vitro 
transfection. The immunostaining, showed no specific expression of GFP in sections 
treated with chitosan/pDNA polyplexes, indicating no transfection of GFP.  
With RT-PCR analyses, the results showed varying degree of GFP expression in 
replicates of same treatment group. The absence of a band in some samples most 
probably was due to absence of transfection as all samples were tested for RNA 
integrity. Despite inconsistent results of the in vivo experiments, the results suggest that 
the chitosan/pDNA polyplexes are capable of transfecting cell in the cochlea and organ 
of Corti in vitro and to some extent in vivo.  
The low correlation of the in vivo experiments with those performed in vitro could be 
partially due to direct application of the chitosan/pDNA polyplexes in the transfection 
medium to the cultures in the in vitro experiments. The differences in transfection 
between in vivo and in vitro experiments might also be due to the exposure sites (scala 
tympani in the in vivo experiments and the perilymphatic and endolymphatic spaces in 
the in vitro experiments) and the administered amount of chitosan/pDNA polyplexes. 
The pDNA concentrations were 13.3µg/ml and 110µg/ml in the in vitro and in vivo 
experiments respectively. The transfection media were 750 µl in the in vitro 
experiments and 100-200 µl in the in vivo experiments depending on the type of the 
osmotic pumps used. Preparation of higher concentration of DNA nanoparticles would 
have resulted in an immediate aggregation. Another possible cause for the inconsistent 
transfection might be the aggregation of nanoparticles in vivo. It is very typical for all 
cationic nanoparticles to aggregate partially at physiological condition, and these 
aggregate are too large to be taken up. This could further reduce the amount of 
available pDNA 
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The absence of transfection of the GFP in the inner ear in vivo might be related to some 
of the factors which have been previously described by (Borchard, 2001) that hinder the 
transfection such as ability of the delivery means of targeting the target cells, ability to 
cross the cell membrane and entering the nucleus [201]. The route of gene delivery to 
the cochlea is complicated by its structural complexity, isolated endolymphatic and 
perilymphatic compartments, and sensitivity of the hair cells to trauma [202]. The 
variability of the results; no expression with the immunostaining and inconsistent 
expression levels with PCR analyses may be due to the pDNA not reaching the target 
cells facing the endolymphatic fluid within scala media. Tan and co-worker suggested 
that there is no dissemination of transfecting agent from the perilymphatic to the 
endolymphatic fluid space especially when using cationic polymer-DNA complexes 
[203]. Contact between the transfecting agent and regions of transfection are important 
to get successful transfection. Since most of the vectors are not able to diffuse through 
the RWM [31,61,147] most efforts in experimental delivery of gene have focused on 
techniques of delivery to the basal turn of the cochlea with the disadvantage of 
potentially damaging the cochlea. Liposomes and some viral vectors can diffuse across 
the RWM to the perilymph although there is no control over the rate of the delivery and 
similar to the delivery of other therapeutic agents to the inner ear, diffusion of vectors 
through the RWM shows a gradient of transfection [61], but for a possible clinical use, 
RWM application seems most feasible and viable route of cochlear gene delivery in 
humans as it is an easy technique, less invasive and less destructive.  
 
5.5 DELIVERY VEHICLES: HYA AND CHITOSANS (PAPERS I-IV) 
In papers I-IV we used sodium hyaluronate (HYA) and chitosans as biodegradable 
vehicles. The method of delivering HYA and chitosans was through a transbullar 
injection using a fine needle to fill the middle ear cavity (Papers I and II). By this route 
of administration we assume that the mixture would be in direct contact with the RWM. 
It was also our intention to test this topical administration which has the advantage that 
the middle ear is kept intact and not injured by any surgery. With the intratympanic 
drug application in experimental animals filling the auditory bulla with drug solution 
[63,177-180,204] drugs do not come into contact with the RWM only. The drugs might 
be absorbed through alternative routes into the inner ear including the annular ligament 
of the oval window, blood and lymph vessels [84,93] thin bone [182] or evacuated 
from the middle ear space by the Eustachian tube[105]. Therefore, the concentration of 
drug in the inner ear is most probably related to the amount of drug coming into contact 
with the RWM. Contact between the RWM and the vehicle carrier is essential.  
Searching for inner ear drug delivery strategies to control the variability associated with 
intratympanic infusions led to the development of sustained release vehicles to 
maintain therapeutic levels of drug on the RWM for a longer time [11,205-207]. Use of 
a biodegradable carrier vehicle is one of the modifications which offer benefits such 
as extended release of the drugs and extended contacts with the RWM so that the 
presence of the drug within the middle ear can be prolonged in comparison to simple 
middle ear perfusions of solutions [106,117]. This in turn can overcome some of the 
variability associated with perfusion into the middle ear cavity. When a drug is 
dissolved or dispersed in the biocompatible polymer, its diffusion is substantially 
slower than when in solution and this contributes to the delivering properties of the 
vehicle. In this way the sustained diffusion into the cochlea across the RWM will be 
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increased and achieve a passive sustained therapeutic agent delivery to the cochlea 
[177,208].  Both the HYA and chitosans displayed no damaging effect on the cochlear 
tissue and were thus considered safe. An ideal biodegradable biomaterial should in 
order to be useful for topical delivery system, degrade in a controlled manner and 
disappear from the site of implant. It should neither cause morphological alterations nor 
elicit any inflammatory reactions [209].    
While delivery of a vehicle can prolong the stay of the drug within the middle ear 
cavity, it does not guarantee control of the rate and duration of drug delivery, or direct 
contact between the drug vehicle and the RWM. In Paper I and II, the left side was first 
injected and 20 minutes later the right side was injected. The left cochleae were used to 
estimate the hair cell loss whereas the right cochleae were used for RWM morphology. 
Thus, the same side was always used for comparisons within the same “experiment”. 
The first ear operated on would probably have a shorter exposure time to the drug 
especially for the less viscous preparation. Also the average length of anaesthesia time 
could have influence on the length of time the liquid neomycin had contact with the 
RWM. The average length of anesthesia time with i.m. ketamine and xylazine was 
45-60 minutes. However the surgical procedure on both sides was finished within 
10-15 minutes in addition to the 20 minutes waiting time after injecting the first side. 
A possible cause of variability is the contact between the drug and the RWM and this is 
a major problem in case of intratympanic injection [42,106]. Due to the increased 
adhesion time of the HYA and chitosans in the middle ear cavity one can expect 
a higher concentration of neomycin transported into the inner ear. However, the HYA 
and chitosans loaded with neomycin seemed not offer any prolonged drug release.  
We used in paper II three different chitosans that gives important insights in the field of 
inner ear drug delivery including in vivo data. Due to the bio-adhesive properties of 
chitosan, it was hypothesized that injected chitosans to fill the middle ear by a single 
transbullar injection, will form an adhesive layer in the middle ear cavity and on the 
RWM. Possibly, adhered chitosan may affect the tight junctions present in the epithelial 
cell layer of RWM thus increasing the permeability of the RWM. Furthermore, drug 
loaded in the chitosan solution may remain longer in contact with RWM due to 
biological properties of chitosan which can promote increased contact and duration of 
exposure with the RWM and eliminate thus some of the variability. Seven days after 
application, the chitosan Ch1 and especially Ch2 were clearly seen macroscopically as 
a gel layer wrapping the cochlea and surrounding structures. In contrast, no depositions 
were observed in the cochleae treated with Ch3. Compared to Ch3, Ch1 and Ch2 
possessed higher molecular weights and lower solubility at physiological conditions 
which may have delayed the degradation. These differences indicate that Ch1 and Ch2 
would probably stay for a longer period of time within the middle ear cavity. Chitosan 
degradation could be delayed after administration without eliciting any inflammatory 
reactions or gross pathological changes or inducement of adhesions in the middle ear of 
mice [105]. 
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5.6 VARIABILITY OF THE OUTCOMES 
There was an individual variation in terms of the effect on the cochlear hair cells and 
thickness of RWM. A number of different factors may contribute to the variability such 
as variations in RWM membrane permeability, attachment or contact of the vehicle and 
solution to the RWM as well as an inter-animal variation in susceptibility to the 
ototoxic effect of neomycin. If air bubbles formed on the RWM, it cannot be 
guaranteed that drugs will enter the cochlea at all [101] 
The delivery of drug across the RWM into the cochlea is dependent also on the 
composition of the vehicle solution. Presence of histamine, prostaglandins, leukotrienes 
and bacterial toxins can increase the permeability of RWM and subsequently the 
passage of substances from middle ear into the inner ear. On other hand deposition of 
inflammatory product on RWM reduces the permeability [44,45,49,55,78,82,84-86].  
The RWM permeability may vary between individual animals within the same species 
[210]. Additional variability arises due to variability of RWM permeability between 
species. One can speculate that permeability of the RWM varies depending on whether 
there are inflammatory conditions in the middle ear and the degree, stage and severity 
of these conditions. These initially increase permeability; subsequently result in 
thickening and scarring so that the membrane become more protective 
[36,44,45,49,60,67-69,78] which decrease the permeability for the subsequent trials of 
inner ear drug delivery. Identification of a carrying agent, which decreases inter-animal 
or interspecies variability, would have significant clinical application. 
Variability may be a result of differences in RWM thickness [51]. The application of 
a drug and its vehicle changes the morphology of the RWM [58] and this will possibly 
affect the permeability of the RWM to drug application later on. Some anatomic 
variations of the round window niche could explain some of the variability of the 
results of the clinical trials for inner ear disorders [38,42,211]. In contrast to the human 
temporal bone, false RWM membrane and tissues covering the RM niche have not 
been described or reported to exist in other species specially the guinea pigs. The 
guinea pig RW niche is shallow, making almost the entire membrane visible and 
uncovered [40-42].  
Once a drug enters the perilymph; its transport is most probably affected by some 
variables. However, the distribution of a drug from the perilymph to deeper 
compartments is not fully known. In addition to diffusion along the length of the 
cochlea, transport through the tissue of the cochlea from one scala to another must be 
considered as well. 
Clearance of the drug from the middle ear cavity is an important issue that is relevant 
and important for the field of local drug delivery to the cochlea. Several mechanisms 
are involved in the clearance of fluids from the middle ear; pumping action through the 
Eustachian tube, contractions of the tensor veli palatini muscle, mucociliary system 
mechanism [212] and osmotic outflow of water from the middle ear as a consequence 
of osmotic pressure gradients [213]. Pumping clearance and mucociliary mechanism 
are suppressed by presence of large volume of fluid in the middle ear cavity [212] and 
this was the case in papers I and II where the middle ear cavity was completely filled 
with the vehicles solution. The muscle pumping mechanism of the tensor veli palatini 
muscle is prevented during anesthesia, which will leads to occlusion of the Eustachian 
tube [214]. 
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6 CONCLUSIONS  
 
The following conclusions were drawn based on the main findings of the thesis: 
 
1- The main finding in paper I is that sodium hyaluronate (HYA) is a safe vehicle 
for medications aimed to pass into the inner ear through the RWM. 
No damaging effects on the cochlear hair cells were shown after local 
administration of HYA. However, the HYA did not provide any benefit by 
increasing RWM permeability to the drug.  
 
2- The use of chitosan as carrier is promising and all the three types of chitosans 
were able to carry and release neomycin, which was then transported into the 
inner ear. Chitosans per se were free from any detectable noxious effect on the 
cochlear tissue. However they caused the RWM to swell and the chitosans did 
not provide any benefit by increasing RWM permeability to the drug. The 
chitosans, especially the glycosylated derivative (Ch3 and SB-TCO) are safe 
and effective carriers for drug and gene delivery through RWM into the 
cochlea. 
 
3- The middle and inner ears are not two isolated cavities but that they interact 
as a combined unit. Thus, the RWM can be seen as a door to the inner ear. 
However, it is not necessarily the only route for passage of substances from the 
middle to the inner ear. 
  
4- The morphological characteristics of the RWM can be changed under the 
influence of carriers and drugs. After exposure to HYA, chitosans and even 
saline, all the layers of the RWM were affected and thickened. The major 
changes were limited to the middle connective tissue layer. HYA and chitosans 
cause no permanent structural damage to the RWM and the RWM retained its 
normal thickness after 28 days exposure to HYA.  
 
5- Despite the inconsistent results, the chitosan/pDNA polyplexes are capable of 
transfecting cell in the cochlea and organ of Corti in vitro and to some extend 
in vivo. With continued research into this field, gene therapy directed towards 
hair cells and SGN may become a clinical reality. 
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